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ABSTRACT	
Introduction: Myeloperoxidase (MPO) is a member of the mammalian heme 
peroxidase superfamily and is mainly expressed in cells of the myeloid lineage. The 
protein plays a crucial role in oxidative burst of activated neutrophil granulocytes and 
consequently in degradation of potential pathogens by production of reactive oxygen 
species. Again, myeloperoxidase leaked or spilled to the intercellular space affects 
host tissue as well. However, this can cause serious damage to key structures 
especially within the central nervous system. A G>A substitution at position -463 
within the promoter region of the MPO gene results in a 25-fold decreased 
expression in cis by disruption of a binding site for transcription factor SP1. At the 
one hand, this may decrease oxidative stress, whereas at the other hand it can also 
lead to worse developed host protection systems against oxidative stress because of 
lower baseline MPO levels.  
Methods: MPO-463G>A genotyping was done by realtime-PCR and allelic 
discrimination using TaqMan® fluorescence labeled probes, results were validated 
by restriction fragment length polymorphism analysis. Assessment of serum MPO 
was conducted by means of enzyme linked immunosorbent assays (ELISA). 
Results and Discussion: Baseline MPO levels did not differ between athletes and 
controls, whereas high serum MPO levels seem to affect rather athletes than 
participants of the control group regarding executional cognitive functions. Moreover, 
we found a statistically significant correlation between MPO and signs of cerebral 
atrophy (CSF-space accentuation). Furthermore, MPO levels and genotype are 
associated with subjective well-being and Geriatric Depression Scale scores. 
Regarding the latter, high serum MPO is a higher risk in participants featuring the 
MPO[-463A] allele. This conforms to previous findings, which indicate that low 
baseline MPO levels can lead to reduced defense mechanisms against oxidative 
stress.    
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KURZFASSUNG	
Einleitung: Myeloperoxidase (MPO), eine mammalische Häm-Peroxidase, wird 
hauptsächlich in Zellen der myeloiden Linie exprimiert. Das Enzym spielt eine 
maßgebliche Rolle im Rahmen der Oxidative Burst Reaktion aktivierter neutrophiler 
Granulozyten und damit im Abbau potentieller Pathogene. Dabei wird vordergründig 
H2O2 zu reaktiven Sauerstoffradikalen umgesetzt. Werden MPO oder dessen 
Endprodukte in den extrazellulären Raum entlassen, kann dies unter Umständen  
auch zu oxidativer Zerstörung des eigenen Gewebes führen. Dadurch können 
zentrale Strukturen innerhalb des zentralen Nervensystems nachhaltig geschädigt 
werden. Eine G>A Substitution an Position -463 innerhalb der Promotorregion des 
MPO-Gens führt zu einer fünfundzwanzigfachen Verminderung der Expression des 
Proteins, da eine starke Bindungsstelle für den Transkriptionsfaktor SP1 aufgelöst 
wird. Dadurch wird einerseits oxidativer Stress vermindert, dies wirkt sich damit aber 
auch auf den Aufbau von Schutzmechanismen vor oxidativem Stress aus. 
Methoden: MPO-463G>A Genotypen wurden durch Sonden-PCR mit 
Endpunktanalyse (TaqMan®-Methode) ermittelt und durch Restriction Fragment 
Length Polymorphism Analyse bestätigt. Der Serum MPO-Spiegel wurde mittels 
Enzyme Linked Immunosorbent Assays (ELISA) gemessen. 
Resultate und Diskussion: Der Basline-MPO Spiegel in AthletInnen unterschied 
sich nicht von dem in Kontrollpersonen, wobei sich höhere MPO-Konzentrationen 
stärker auf das Abschneiden von AthletInnen als von KontrollparticipantInnen in 
Kognitiven Tests auszuwirken scheint. Außerdem konnte ein Zusammenhang 
zwischen MPO und Zeichen zerebraler Atrophie (Liquorraumakzentuierung) 
gefunden werden. Weiters hängen Bewertungen des subjektiven Wohlbefindens und 
Scores der Geriatric Depression Scale mit MPO serum Konzentrationen und 
Genotypen ab. Bezüglich des Letzteren wurde festgestellt, dass hohe MPO-Spiegel 
nur in Trägern des MPO[-463A] Allels ein Risiko darstellen. Dies bestätigt die 
Hypothese, dass niedere MPO-Spiegel bei besagtem Allel auch geringere 
Abwehrmechanismen vor oxidativem Stress bedingen.  
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1. INTRODUCTION	
1.1. MYELOPEROXIDASE	–	HISTORY	OF	AN	ENZYME		
In the meantime, the discovery of myeloperoxidase dates back as many as 70 years1 
cited by 2, when Kjell Agner from the Serafimer Hospital in Stockholm, Sweden3, 
identified an enzyme with peroxidase activity in leukocytes present in tubercular 
empyema and named it Verdoperoxidase. Further investigations on this enzyme took 
place hesitantly. However, this was due to difficulties in myeloperoxidase isolation 
resulting in only small amounts of the enzyme, hardly sufficient for extensive 
analyses4 cited by 5. As recently as the induction of a leukemic tumor called chloroma 
as an artificial source of leukocytes was possible in rats, production of sufficient 
amounts of the scarce protein was no longer a problem, since chloroma cells of 
young rats show a three-fold increased (6 %) concentration of myeloperoxidase, 
which moreover causes the green color of the solid tumor 5.  
1.2. GENETIC	BACKGROUND	OF	MPO 
Myeloperoxidase (EC 1.11.1.7) is a member of the mammalian heme peroxidase 
superfamily and is therefore a homologue to lactoperoxidase and eosinophil 
peroxidase6,7 cited by 2. The coding regions of the three peroxidases are arranged next 
to each other at the q-arm of chromosome 17, suggesting a common origin via gene 
duplication8 cited by 2 (see Fig. 1).  
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Moreover, the promoter sequence of MPO contains a 5’-upstream single nucleotide 
polymorphism (NG_009629.1:g.4535G>A; NT_010783.15:g.21632914C>T; 
rs2333227; MPO-463G>A)10. Due to its critical position within a possible binding site 
of transcription factor SP1 and simultaneously within the first half-site of a retionoic 
acid receptor element (RARE)11, this mutation is of special functional interest. In 
detail, position -505-200 represent a so-called Alu-element 12,13 cited by 11.  
However, these elements make up about 5% of the human genome. These 
retrotransposons, genetically derived from 7SL, have been spread over the entire 
genome via transcription by RNA polymerase III followed by reverse transcription 
and subsequent reintegration into the genome at many different sites, thus leading to 
development of seven distinct families of Alu-elements.14,15 cited by 11       
Additionally, Alu-elements show regulative features regarding their genetic 
environment16-21 cited by 11. Thus, especially subclasses III and IV contain a hormone 
response element HRE21 cited by 11, composed of hexamer motifs according to the 
consensus sequence AGGTCA. Hence the motifs can be recognized as a binding 
site for numerous nuclear receptors, e. g, vitamin D receptor VDR and steroid 
receptors as well as retinoic acid receptor RAR and thyroid hormone (T3) receptor 
TR22-25 cited by 11. Receptors of the RAR/TR family need retinoid X receptors RXR to 
form a heterodimer26-30 cited by 11, thus binding direct repeats of two neighboring 
hexamer half-sites31-33 cited by 11.   
Figure	1:	The homologue enzymes eosinophil peroxidase (EPX), lactoperoxidase (LPO) and 
myeloperoxidase (MPO) are coded on the q-arm of chromosome 17. There is evidence, that this 
three heme peroxidases derived from a common origin via gene duplication8. The protein of the 
coding region “Meckel Syndrome, type 1” (MKS1) is required for formation of the primary cilium in 
ciliated epithelial cells. Figure based on: 9, retrieved (15.03.2011) from http://www.ncbi.nlm.nih.gov/gene/4353# 
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Preceding MPO, the said HRE consists of four half-sites reaching from position -463 
to -437, again related to the consensus sequence AGGTCA. The first and the last 
two elements (orientated from 5’ to 3’ of the gene) form a motif called DR-2 and are 
separated by only two base pairs. Both of the middle hexamers make up DR-4, thus 
being separated by 4 base pairs. DR-2 represents a retinoic acid receptor element 
RARE, DR-4 is in turn typical for thyroid hormone response elements TRE. However, 
there is no evidence for in vivo importance of RAR or TR mediated regulation of 
MPO, but of transcription factor SP1, sharing a 10 bp consensus sequence within the 
very first DR-2 element.11 
 
1.3. MPO	AND	TRANSCRIPTION	FACTOR	SP1 
Not long ago, a sequence-specific regulation element, specificity protein 1 (SP1), has 
been found within the promoter of the tumor virus SV 4034 cited by 35.  
This transcription factor binds GC-rich sites, so-called GC-boxes by three C-terminal 
zinc finger-motifs, each consisting of a Cys2His2 sequence. Moreover, the protein 
consists of a buttonhead (Btd) box which plays a role in the transactivation activity of 
the transcription factor, glutamine-rich subdomains, which mediate the regulative 
activity, serine/threonine-rich target sites for post-translational modification as well as 
an N-terminal Sp box representing an endoproteolytic cleavage site.36 cited by 35 In cells 
of the myeloid lineage, some twenty specific genes are known that feature GC-
boxes, which thus can be regulated by transcription factor SP1 or its related factor 
SP3. 35 However, myeloperoxidase is one of it11 cited by 35. 
The previously mentioned MPO-463G>A single nucleotide polymorphism finally 
modifies hexamer 1 of the most 5’ DR-2 motif within the promoter-Alu element at 
position 5. Interestingly, this alternation destroys a strong binding site for 
transcription factor SP1 leading to a 25-fold decrease in gene expression of MPO 
compared to the wild type promoter.11 
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1.4. EXPRESSION	OF	MPO	–	AN	INTRODUCTION 
The protein is mainly expressed in cells of the myeloid lineage, especially  in 
precursors of neutrophil granulocytes. As shown in figure 2, transcription of MPO 
decreases with increased differentiation. Thus, myeloperoxidase is mainly 
synthesized in promyelocytes and promonocytes residing in the bone marrow37 cited by 
2. 
Figure	2:	Expression of myeloperoxidase has been shown in a multitude of cell types related to 
the myeloid lineage, although in different concentrations. In detail, the amount of MPO mRNA 
decreases with the stage of cell differentiation. Subsequently, high levels of MPO mRNA can be 
found in myeloblasts, monoblasts and promyelocytes, whereas circulating cells contain little 
mRNA. Moreover, neutrophils contain high amounts of MPO protein compared to monocytes and 
tissue macrophages. Whether MPO synthesis is reinitiated in vivo in the latter has not been 
proven yet37 cited by 2. Figure obtained from: 2  
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1.5. NEUTROPHIL	GRANULOCYTES	
To discuss the function of myeloperoxidase, it is inevitable to describe first its major 
source, the neutrophil granulocyte. Neutrophil granulocytes, hematopoetic cells of 
the myeloid lineage, are cells of the innate immune system produced from 
myeloblasts within the bone marrow by formation of different progenitor and 
intermediate cell types (see also figure 3) as a response to stimulation with 
granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-
stimulating factor (GM-CSF)38,39 cited by 40.  
Accordingly, neutrophil granulocytes and their precursors respectively can be found 
in different body compartments: the bone marrow, the circulation and in tissue in 
general. Cells residing in each pool thereby sustain a dynamic equilibrium of 
circulating cells, whereas young, so-called neutrophil band granulocytes migrate from 
the bone marrow to the circulation, where the total population of neutrophiles can be 
subdivided into a marginal and a circulating granulocyte pool41 cited by 40. Cells of the 
marginal pool reside at the endothelium and are of a significantly higher 
chronological age than circulating cells. However, this difference in cell age could be 
verified by measurement of granulocyte alkaline phosphatase activity in circulating 
blood before and after stimulation of cell migration from the marginal to the 
circulating pool. Granulocyte alkaline phosphatase activity is elevated in mature, 
polymorphnuclear granulocytes and can therefore be seen as an eligible marker for 
the mean chronological age of a neutrophil granulocyte population 42. The third pool, 
the tissue neutrophiles, consists of cells that have penetrated the vessel wall41 cited by 
40. 
1.6. NEUTROPHIL	GRANULE	COMPONENTS	
Again, a morphological characteristic of neutrophils is the presence of different 
granules in the cytoplasm. These vesicles had already been described by 
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Metchnikov and Ehrlich as early as the turn of the 20th century 43,44 cited by 40. In 1952, 
the physiological importance of the granules could be studied in patients’ featuring 
abnormal granules as a result of the autosomal recessive Chediak-Higashi-
Steinbrinck-syndrome45 cited by 40. Later, the role of neutrophil granules in 
phagocytosis was demonstrated by means of electron microscopy and phase 
contrast microscopy. In this context, the fusion of granules with membrane coated 
compartments originating from ingestion of extracellular particles resulting in a 
phagosome, could be shown46,47 cited by 40.   
The disparity between the types of granules results from the existence of different 
membrane and matrix proteins, each combination more or less specific for the 
respective kind of granule. In a nutshell, the granules can be traditionally subdivided 
into peroxidase positive (azurophil or primary granules) and peroxidase negative 
(secondary granules) vesicles48,49 cited by 50, although in fact there is a vast multitude 
of different types regarding structure (content) and function (disposition for 
exocytosis or fusion with the phagosome) (Table 1) 50.  
The heterogeneity of the granules arises from their time of production as proposed 
by the targeting-by-timing hypothesis, which reveals that expression of granule 
matrix and membrane proteins occurs staggered depending on the degree of 
maturation from promyelocyte to polymorphnucleic neutrophils. That means that 
granules assembling at the same time pack up more or less the same available 
combination of granule proteins51 cited by 50. However, consecutively expressed 
proteins like elastase underlie a sorting process what is yet not very well 
understood52 cited by 50. These different granules with their own specific content 
mediate the antimicrobial effect that neutrophils need to cope with their duties in 
cellular innate immunity 50. 
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   Membrane Proteins 
Azurophil granules Specific granules Gelatinase granules Secretory vesicles 
N.a. CD11b/CD18, CD66, 
CD67 
CD11b/CD18, CD67 CD11b/CD18, CD67 
N.a. GP91phox/p22phox GP91phox/p22phox GP91phox/p22phox 
N.a.  MMP26 MMP26 
N.a. TNFRc, uPARc TNFRc LIR1-4, -6, -7, -9c; CD35; 
CD16 C1q-R; IFN-αR1 
and IFN-αR2c; IFN-γR1 
and IFN-γR2c; TNFR1 
and TNFR2c; IL-
(1,4,6,10,13,17,18)Rc; 
TGF-βR2c; CXCR-1c; 
CXCR-2c; CXCR-4c; 
CCR-1, -2, -3c; 
Ig(G,A,E)FcRc; TLR-1, -
2, -4, -6, -8c; CD14, 
MyD88c; MD-2c; fMLPR, 
TREM1c  
CD63, CD68  
presenilin 
SNAP-23, VAMP-2, 
Stomatin, PGLYRPc 
SMA -23, VAMP-2, 
Nramp1 
SNAP-23, VAMP-2, 
Nram 1, al aline 
phosphatase, DAF, 
CD10, CD13 
Matrix Proteins 
Elastase, cathepsin 
G, proteinase 3 
Collagenase, 
Gelatinase, uPA, 
cystatin Cc, cystatinFc 
Gelatinase, 
arginase1 
Plasma proteins 
Defensis, BPI, MPO, 
lysozyme 
hCAP18, NGAL, 
B12BP, lysozyme, 
lactoferrin, 
haptoglobin, 
pentraxin 3, 
prodefensin 
Lysozyme N.a. 
Sialidase, 3-
glucoronidase, 
azurocidin  
α1-anti-trypsinc, 
SLPO, orosomucoid, 
heparanase, β2-
microglobulin, 
CRISP3 
β2-microglobulin, 
CRISP3 
N.a. 
 	
Table	1:	Neutrophil granules and granule proteinsa,b Modified table: 50.  
“aAbbreviations: B12BP, vitamin B12 binding protein; CRISP, cysteine-rich secretory protein; DAF, decay-
accelerating factor; Gp, granule protein; LIR, immunoglobulin-like receptor; n.a., not applicable; uPA, 
urokinase plasminogen activator. 
bLocalization of proteins in the matrix and the membrane of neutrophil granules and secretory vesicles. The 
list is not completely exhaustive but illustrates the major classes of proteins found in the various types of 
neutrophil granules. Yellow, adhesion molecules; blue, receptors; orange, antibacterial proteins; green, 
proteases; colorless, other functional classes of proteins. 
cThe localization is inferred from the gene expression profile according to the targeting-by-timing hypothesis 
but has not been confirmed at the protein level.” 50 
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Figure	4:	During their life cycle, neutrophil granulocytes meet two distinct bursts of gene expression. 
While the first occurs at the early myelopoetic phasis in myeloblasts (green bars), the latter happens 
mainly during diapedesis and phagocytosis (light blue bars). Moreover, sequential transcription of 
neutrophil granule proteins is expanded to myelocytes and metamyelocytes (red bars) as well as late 
metamyelocytes and early band cells (dark blue bars). Figure obtained from: 50 
“Abbreviations: FLT, FMS-like tyrosine kinase; G-CSF, granulocyte stimulating factor; GM-CSF, 
granulocyte-macrophage stimulating factor; HGF, hepatocytes growth factor; IL, interleukin; IFN, 
interferon; MCP, monocytes chemoattractant protein; MD, myeloid differentiation; Mf, macrophage; 
MIP, macrophageinflammatory protein; MY, myelocyte; PM, promyelocyte; PMN, polymorphonuclear 
granulocyte; TGF, transforming growth factor; TLR, Toll-like receptor; TNF, tumour necrosis factor; 
TREM, triggering receptor expressed on myeloid cells.” 50	
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Again, in literature on neutrophil transcription analysis, two bursts of transcriptive 
activity were described (see figure 3) 50. The first burst was appointed during 
maturation within the bone marrow, including transcription of granule proteins, the 
p53 system and several receptors. The second burst occurs in the last stage of 
neutrophil life cycle: the exuded tissue neutrophil. During this, mainly 
cytokine/chemokine receptors, Fc receptors for recognition of antibodies’ Fc 
(fragment crystallizable) domains, pattern recognition receptors (PRR), 
cytokines/chemokines and components for subsequent apoptotic pathways are 
produced. 
1.7. PHAGOCYTOSIS	IN	NEUTROPHILS	
As already mentioned, a crucial physiological function of neutrophil granulocytes is 
their microbicidal effect, which mainly rests upon exocytosis of antibacterial peptides 
and proteases as well as phagocytosis with production of hypochlorous acid and 
reactive oxygen species53,54 cited by 40. The latter is done by peroxidases such as 
myeloperoxidase 55, which are stored in the cells’ primary granules. 
However, how does myeloperoxidase establish its microbicidal effects? To answer 
this question, we have to focus on the molecular processes occurring during a 
cellular innate immune response mediated by neutrophil granulocytes resulting in 
degranulation of primary granules. This process can either be induced by 
phagocytosis of antigens or by surfaces coated with complement molecules or 
antibodies. In the first case, the granule proteins and thus myeloperoxidase is 
released into the developing phagosome and therefore mostly stays inside the 
neutrophil, altough some enzyme can leak into the outside due to incomplete 
constriction of the early phagosome from the cell membrane. In the second case, 
however, the granule content is directly released to the outside56 cited by 55.   
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In professional phagocytes such as neutrophil granulocytes, phagocytosis refers to a 
complex cycle from recognition of apoptotic cells 57 or a bacterial pattern 58-60, its 
degradation, and in case of the latter presentation on the cell surface by MHC-II 
complex to cells of the adapted immunity61 cited by 58. To simplify matters, 
phagocytosis of apoptotic cells will not be discussed below.  
Thus, the process of microbe ingestion starts either with detection of a pathogen-
associated molecular pattern (PAMP) by PRRs or recognition of an antigen, 
opsonized by complement or antibodies, by the respective complement receptor or 
Fc receptor62. Whereas both of the latter as well as some PRRs can trigger 
invagination of cell membrane and thus phagocytosis themselves, there is no fair 
evidence on the contribution of toll-like receptors (TLR), a diverse family of PRRs 
against a variety of molecular patterns60, to endocytosis. Stadlbauer, Leendertsee 
and Lee 63-65 concluded, that absence of different TLRs does not influence 
phagocytic activity whereas Bellochio and Hayashi 66,67 found an increase in 
phagocytic activity after stimulation of TLR.   
1.7.1. A	SIDE	NOTE	ON	TOLL‐LIKE	RECEPTORS		
	
In this connection, I assume that a short excurse to the field of TLRs will be 
apologized. However,  currently thirteen distinct TLRs  are known in mammal 
cells68, each specified on the recognition of a small subset of antigens. They 
can be grossly classified into two subtypes depending on their location either on 
the cell surface or intracellular. The first subtype (TLR 1, -3, -4, -5, -6) is 
spezialised in detection of bacterial lipoprotein and lipoteichoic acid 
(TLR1+TLR2, TLR6), lipoprotein S (TLR2) and flagellin (TLR 5). The 
intracellular subtype includes receptors (TLR3, -7, -8, -9) focused on 
recognition of69 cited by 70 mainly viral dsDNA (TLR3), ssRNA (TLR7, TLR8 71) 
and unmethylated CpG-DNA (TLR9)69 cited by 70. In neutrophil granulocytes, 
TLR3 is not expressed67 cited by 70.   
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After recognition of the respective antigen by its receptors, a cascade resulting in the 
internatlization of the particle is started, whereas the molecular processes depend on 
the respective receptors involved. Engulfment of particles opsonized by complement 
is accomplished by simply sinking into the cell, whereas Fcγ-receptors induce active 
inclusion by formation of pseudopods surrounding the IgG-opsonized particle72 cited by 
62. Subsequently, a great many of signaling events is started. Phagocytosis of 
unopsonized particles seems to be dependend on lipid rafts73-75 cited by 72.  
In case of FcR-mediated phagocytosis (see fig. 5), however, the first step in cell 
signaling is phosphorylation by a Src-family member of the cytosolic domain of the 
FCR or of associated proteins containing an immunoreceptor tyrosine-based 
activating motif (ITAM)76,77 cited by 72. Further signal transduction via phosphorylation is 
done by another tyrosine kinase. For instance, in IgG-mediated phagocytosis, Syk 
will be recruited78,79 cited by 72, resulting in activation of several adaptor proteins 
including LAT80 cited by 72, SLP-76, BLNK81 cited by 72, Crk1 82 cited by 72 and Nck83 cited by 72 
and Fyb/SLAP (84 at that time unpublished data mentioned by 72), as well as 
generation lipid mediators such as phosphatidylinositol-4,5-bisphospate85 cited by 72 
and 3’-phosphoinositides by phosphatidylinositol-3-kinase (PI3K)72. The latter is 
involved in activation of phospholipase c (PLC), which via production of 
diacylglycerol (DAG) in turn activates proteinkinase C (PKC) isoforms involved in 
particle uptake at the evolving phagosome86 cited by 72. Again, there is evidence that 
phosphoinositides and anionic phospholipids respectively play a key role in 
sustaining electrostatic interactions with polycationic protein motifs87. In terms of 
cytoskeletal remodeling, Rho-GTPase family members72 (including RacI and 
Cdc4288) induce focal assembly of F-actin, whereas Gelsolin triggers its severing in 
order to get short filaments72. The first is supported by contribution of ARF689,90 cited by 
72; ARF6 further acts as a co-factor in PIP2 generation89 cited by 72. Actin remodeling is 
also catalyzed by dephosphorylated Cofilin enhancing actin filament turnover91,92 cited 
by 72.  
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Figure	5:		Depiction of signal transduction pathways in Fcγ-receptor mediated phagocytosis. 
Umpteen components are still hypothetical and unproven and thus indicated by “?”. Figure 
obtained from: 72  
 
Indeed, it is a long way from a phagosomes’ birth at the cell surface to its final 
destination as a matured phagolysosome. This transformation process contains 
changes in both, the chemical conditions within the phagosome lumen as well as the 
composition of protein93. The interchange of molecules between a maturing 
phagosome and other cell organelles has been described best by studying especially 
membrane-bound components. Hence, the investigations resulted in a decrease of 
cell surface markers coupled by an increase of protein typically for early and late 
endosomes as well as lysosomes94,95 cited by 93 suggesting an onward fusion with the 
respective organelles96 cited by 93, most likely by so-called “fusion/fission events”93, 
better known as “kiss and run fusion”93.  As suggested by Duclos et al.97 cited by 93, 
these events could be regulated by Rab GTPases Rab5 and Rab7. Additionally, 
Rab7 is thought to bind its effector RILP98 cited by 93, a protein attached to the 
microtubule-bound dynein-dynactin motor complex, resulting in anchoring at the 
microtubules system99 cited by 93, which thus acts as a guide rail for maturing 
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phagosomes on their way into the inner cell100 cited by 93.  During this, for instance 
proteins associated to lipid rafts101 cited by 93 (flotillin-1, proton pump) as well as 
components of the NADPH oxidase102,103 cited by 93, which is mainly involved in killing 
of ingested bacteria, are recruited to the phagosome. 
Lipid components are estimated to play key roles in phagosome maturation. On that 
account, especially phosphatidylinositol 3-phosphates (PI(3)P) are held in high 
esteem. These lipids, most likely generated by the class III PI3K 
(phosphatidyinositol-3 kinase), have been identified to accumulate on the cytosolic 
leaflet of early endosomes104 cited by 105 and interact with proteins containing FYVE and 
PX domains respectively106,107 cited by 105 that contribute to phagosome maturation105. 
Moreover, PI3P is also involved in deactivation of Rab5108 cited by 87. Furthermore, 
changing the composition of membrane leaflets influences its electrostatic 
constitution by altered surface charge87,109 cited by 87 thus causing changes in the 
recruitment of cationic molecules. This has been shown for phagosomal membrane 
layers during maturation87.    
The sense of this stepwise maturation is to progressively adjust the proteolytic and 
microbicidal conditions of the phagosomal lumen93, including the previously 
mentioned fusion of myeloperoxidase positive granules with the phagosome. This 
brings us right back to the function of myeloperoxidase, which finally will be 
discussed below.    
1.8. CHEMICAL	PROPERTIES	AND	REACTIONS	OF	MYELOPEROXIDASE		
The catalytic system of myeloperoxidase (figure 6A) consists of the enzyme itself, the 
oxidative species H2O2 and of course a reagent to be oxidized2, for instance a 
bacterial component. However, hypochlorous acid (HOCl) leads instead of H2O2 to 
the same reaction110 cited by 55. The first step of the following redox-reaction includes 
the formation of compound I. In detail, generation of compound I occurs by oxidation 
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of the ferric heme center of MPO [MPO-Fe(III)] resulting in a oxy-ferryl group (MPO-
FelV=O). As a byproduct, H2O2 is reduced to H2O.2 
Compound I acts as the primary catalytic complex in further oxidations of halides and 
pseudohalides111 cited by 2, alias halogenation cycle. During this, two electrons are 
transferred from the reduced oxy-ferryl group to halides resulting in the formation of 
hypohalous acids as well as the recycling of compound I to the ferric form of 
myeloperoxidase6 cited by 2.  
Of course, not only halides can act as reactants for myeloperoxidase compound I. 
Other reactants can be oxidized as well by the so-called peroxidase cycle111 cited by 2. 
This pathway includes the gain of a single electron from an oxidizable reactant 
generating compound II6 cited by 2 containing an oxy-ferryl heme center without the π-
cation radical of the porphyrin ring (MPO-FeIV-OH) resulting in a reduced activity2. 
Further oxidation of comparable reactant leads to reformation of ferric MPO 2 under 
abstraction of H2O. Otherwise, regeneration of the native, active myeloperoxidase 
can be conducted112-114 cited by 55 or at least accelerated2 by exceeding superoxide 
radical O2⎯ ̇ (figure 6B).  
This suggests a potentially regulative role of O2⎯ ̇ by maintaining the active form of 
MPO in an environment containing excess H2O2. In this case, oxidative damage at 
inflammatory sites would be increased by O2⎯ ̇ due to elevated production of HOCl by 
the regenerated enzyme in the presence of H2O2. This hypothesis can be supported 
by the anti-inflammatory effect of superoxide dismutase, an enzyme that converts 
O2⎯ ̇ to H2O2 and thus eliminates the superoxide radical.112,114,115 cited by 55 However, 
the physiological importance of O2⎯ ̇ in activation of myeloperoxidase still leaves open 
questions, bearing the role of other reductants, as for instance ascorbic acid in mind, 
which show a considerably faster conversion of compound II to the active state 116,117 
cited by 55 than the superoxide radical.   
A third intermediate of myeloperoxidase, compound III (MPO-Fe2+O2), can be 
derived either from compound II by reaction with H2O2 or from native ferric state in 
presence of O2⎯ ̇ 2. This unstable compound III, however, shows a half-decay time of 
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only a few minutes at room temperature, rather quickly decaying to the ferric 
state118,119 cited by 55.  Nevertheless, there is evidence that even this unstable 
intermediate could act as a catalytically active kind of myeloperoxidase. That arises 
from the fact, that compound III is present in intact, stimulated neutrophils120 cited by 55 
and that it potentially reacts with electron donors119,121-123 cited by 55 as well as 
acceptors123 cited by 55. 
Figure	6:	A Reactive compounds 
derived from myeloperoxidase. 
The figure shows the halogenic 
cycle (indicated by 2) as well as 
the peroxidase cycle (3,4). Figure 
obtained from 2 referring to 111,124 
B Balance of reactive 
intermediates with respect of a 
possible regulative role of O2⎯ ̇, 
keeping myeloperoxidase in its 
active form. Figure obtained from 
55 referring to 125 
	
	
B	
A	
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1.9. THE RESPIRATORY BURST OXIDASE – WHERE DOES ALL THAT H2O2 COME FROM?  
As mentioned before, the function of myeloperoxidase is closely linked to the 
presence of hydrogen peroxide H2O2. Consequently, we need to ascertain possible 
sources of this major component. In his latest review on myeloperoxidase, Seymour 
Klebanoff55 proposes several resources, some possibly contributing more to the 
physiological H2O2 concentrations available for myeloperoxidase than others.  
1.9.1. PHAGOCYTIC SOURCES OF H2O2 
However, the phagocyte NADPH oxidase complex is considered as an 
exceedingly important provider (figure 7), as we learn from patients suffering 
from chronic granulomatous disease CGD, which have to sustain recurring 
infections and formation of granulomas consisting of fused monocytes and 
macrophages, that are deficient in elimination of their ingested pathogens126 cited 
by 127. 
The protein complex is made up of four oxidase-specific components termed 
p22phox, p47phox, p67phox and gp91phox (whereas phox abbreviates phagocyte 
oxidase) as well as a Rac1/2 GTPase and exists in combination with regulative 
p40phox and Rap1A 128 cited by 127.  gp91phox is supposed to contain flavin and 
heme as a binding side for NADPH, which is required for further electron 
transportation55. However,  together with p22phox this compound has been 
shown to form a membrane-bound heterodimer known as b-cytochrome129 cited 
by 55.  
Again, the b-cytochrome heterodimer holds adequate physical features 
(absorption peak at 558 nm) for oxidation of molecular O2 and subsequent 
generation of O2⎯ ̇. Upon stimulation of neutrophils, b-cytochrome residing in 
membranes of specific granules and secretory vesicles is introduced into cell 
membrane or phagosomal membrane, hence fusing with the cytoplasmic 
components p40phox, p47phox and p67phox. Thus activated NADPH oxidase forms 
O2⎯  ̇by transferring an electron across the membrane to O2 residing at the cell 
surface or the phagosome lumen respectively. 55  
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Featuring a pKa of 4.8, consequently at a pH of 4.8, O2⎯  ̇occurs in equal parts 
with its protonated species HO2 ̇ . At the same time, spontaneous dismutation 
via formation of O2 and H2O2 by reaction of two molecules O2⎯ ̇ occurs, thus 
generating our desired hydrogen peroxide for the first time. At a higher pH, the 
velocity of H2O2 formation by spontaneous dismutation radically lags behind the 
rate achieved by superoxide dismutase (SOD)-catalysed reaction. However, 
there is no evidence for transportation of SOD into the phagosome, although 
the enzyme could be part of the ingested pathogen. 55 
1.9.2. EXTERNAL SOURCES OF H2O2 
Mitochondrial metabolism producing small amounts of H2O2 could serve as 
another source of hydrogen peroxide for the myeloperoxidase system. 
However, whether the oxidant is released from its origin remains still unclear.  
 
Additionally, a NAD(P)H oxidase present in vascular cells130-135 cited by 55 is 
supposed to provide H2O2 for myeloperoxidase released to the blood stream 
thus dripping into the endothelium. There, the myeloperoxidase system is 
considered to play a role in vascular signaling via formation of nitric oxide.136 
cited by 55  
Moreover, non-phagocytic homologues of the phagocyte NADPH oxidase 
known as NOX (NADPH oxidase) or DUOX (dual oxidase) enzymes137,138 cited by 
55 could also somehow contribute reactive oxygen species (ROS) to the 
myeloperoxidase system55.  
Soluble oxidases as for example xanthine oxidase , amine oxidase and glucose 
oxidase have been shown to form H2O2, whereas the first is involved in ROS 
production causing reperfusion injury to ischemic tissue139 cited by 55. 
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Another possible source of H2O2 could be represented by lactic acid bacteria140 
cited by 55, e. g. certain strains of pneumococci, streptococci and lactobacilli as 
well. 55 
However, the latter act as physiologic symbiotes at the vaginal mucosa. The 
immunological importance of lactobacilli as a microbial source of H2O2 is 
supported by the finding, that women harboring strains of lactobacilli that are 
not capable of forming H2O2 are significantly predisposed for bacterial 
vaginosis141 cited by 55,  as well as several other infections of the urogenital 
tract142 cited by 55.  
1.10. MICROBICIDAL	EFFECT	OF	MYELOPEROXIDASE‐DERIVED	OXIDANTS 
The microbicidal effect of myeloperoxidase is mainly due to generation of three 
specifiable groups of oxidants by its catalytic complexes, depending on its respective 
reactant Cl⎯, NO2⎯ or tyrosine2 (figure 7).  
 
 
	
29	
	
Figure	7:	The NADPH-oxidase complexes residing at the cell membrane and the phagosomal 
membrane respectively (possibly together with superoxide dismutase SOD) keep supplies of H2O2 for 
the myeloperoxidase system coming. Moreover, formation of different microbicidal compounds by the 
myeloperoxidase + H2O2 system depends on the respective reactant Cl⎯, NO2⎯ or tyrosine. Figure 
obtained from 2 
	
Related to the first reactant Cl⎯, production of the following highly reactive 
components is enabled, which will be further discussed: e. g. hypochlorous acid 
HOCl, chloramines, hydroxyl radicals HO ̇, ozone O3 and singlet oxygen 1O2 55,111 cited 
by 2. 
As a weak acid featuring a pKa of 7.53, HOCl deprotonates incompletely, under 
standard conditions resulting in a composition of the acid and its anionic base, 
hypochlorite OCl-. A decrease in pH, as it progressively occurs during phagosome 
maturation, thus leads to a shift in favor of the acidic species. 55  
When HOCl reacts with excess chloride, highly reactive143cited by 55 molecular chlorine 
(Cl2) will be generated144-146 cited by 55. Subsequently, this molecule is able to oxidize a 
plethora of functional groups present on microbes, including sulfhydryl and sulfur-
ether groups, iron-sulfur centers, heme as well as unsaturated fatty acids55. 
Accordingly, multiple metabolic functions are affected: loss of membrane transport147 
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cited by 55, and adenylate energy reserves148 cited by 55 as well as demolition of electron 
transport chain at the microbial membrane149 cited by 55 and elimination of DNA 
synthesis, e.g. by detaching the chromosomal origin from the bacterial cell 
membrane150 cited by 55. Additionally, extension of antimicrobial activity in time and 
space is conducted via durable chloramines. These compounds are formed by 
reaction of HOCl with nitrogen-containing molecules and occasionally degrade to the 
respective aldehyde151,152 cited by 55, maintaining their oxidizing properties. However, 
damage by HOCl leaking to the neutrophil cytoplasm can be diminished by high 
amounts of taurine153,154 cited by 55 via reaction to taurine chloramine, a less reactive 
and hence toxic compound. This could be considered as a technique by which the 
proverbial snake bears its own poison, whereas including more recent findings one 
could tend to put this possible protective mechanism in question2. More precisely, 
taurin is classified as a possibly cytotoxic, long lived oxidant155 cited by 2, selectively 
targeting creatinine kinase, glyceraldehyde-3-phosphate dehydrogenase and critical 
cysteins156 cited by 2.  
Small amounts of HO  ̇produced by the myeloperoxidase system157 cited by 55 result 
from HOCl reacting with O2⎯ ̇ generating O2 and Cl⎯ as by-products55. However, this 
compound is extremely reactive and thus features just a slight spatial radius. 
Forming HCO3 ̇ by reaction with CO2, another antibiotic oxidant has been produced 
that finds its preferred environment within the phagosome.158 cited by 55 
Formation of 1O2 by the myeloperoxidase system according to  
H2O2 + OCl⎯  1O2 + H2O + Cl⎯ has be shown experimentally under physiological 
conditions159 cited by 55, whereas the situation in vivo still needs further evaluation55.  
O3 is further supposed to be produced by neutrophil respirative burst with 
consumption of  1O2 160 cited by 55. Moreover, the microbocidal effects of H2O2 and O3 
reinforce each other55.    
 
Secondly, inflammation features an increase of NO2 (>200 µM) within the affected 
environment, providing a rich variety of reactants for myeloperoxidase compound I 
161-163 cited by 2 . Nitrite NO2⎯ and myeloperoxidase + H2O2 react to the unstable 
compound nitrogen dioxide radical NO2 ̇ , which promotes lipid peroxidation and 
nitration of proteins163-169 cited by 2, as well as oxidation of the amino acid tyrosine, thus 
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producing nitrotyrosine, a marker of oxidative stress170-172 cited by 2. The latter is again 
attributed to inflammatory cellular dysfunction163,165 cited by 2.    
 
Tyrosine as a third direct reactant of myeloperoxidase and H2O2 can thus be 
converted into the tyrosyl radical in absence of Cl⎯55. Subsequently, this compound 
can form either free or protein-dityrosine linkages 173,174 cited by 55. Furthermore, 
tyrosine peroxide can be produced from tyrosyl radical reacting with superoxide175 
cited by 55.  
1.11. PATHOPHYSIOLOGICAL	IMPORTANCE	OF	MPO 
As reported by van der Veen  et al.2, the prevalence of hereditary MPO deficiency in 
Europe and the United States of America ranges between 1:1000 and 1:4000176-180. 
Indeed, these individuals show significantly higher incidences of infectious as well as 
chronic inflammatory diseases181 cited by 2, although the reported patients were not 
“extremely more susceptible to infections” 181 cited by 2 as it is known for patients 
suffering from chronic granulomatous disease, expressing a dysfunctional NADPH 
oxidase thus lacking sufficient generation of H2O2 182 cited by 2. Moreover, the 
microbicidal activity of MPO deficient neutrophils exceeds that of neutrophil 
granulocytes treated with peroxidase inhibitors183 cited by 2. However, these findings 
indicate a possible compensation of a dysfunctional MPO-system in-vivo by MPO-
indipendent mechanisms 2.   
1.12. MPO	AND	COGNITIVE	DECLINE	
“The term cognitive decline actually reflects a continuum of cognitive changes; some 
are considered to be within the spectrum of normal aging, whereas others exceed 
expected decline and are categorized as mild impairment.”184 
However, the line between normal and pathologic decline, also referred as mild 
cognitive impairment (MCI) or cognitive impairment without dementia, are blurred. 
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Usually, diagnosis of MCI occurs via testing and subsequent evaluation of cognitive 
domains such as language, orientation, memory and executive functions. 184  
Moreover, cognitive decline may pose a risk for progression to MCI and dementia184, 
whereas cognitive decline and dementia overlap or more exactly “may represent a 
continuum of disease”185 cited by 186.  
To the patients suffering from it, cognitive decline means a certain condition of 
elevated disability and thus decreases autonomy and quality of life. However, said 
condition shows multiple reasons ranging from biological to environmental, social 
and even behavioral factors and most of them remain still unknown. 184 
A potential contribution of oxidative stress factors to cognitive decline has been 
suggested by numerous publications. Thus, production of free radicals during 
oxidative processes may promote cognitive impairment by either increased 
atherosclerosis and thrombosis187,188  or selective brain damage189. The latter could 
be due to a special sensitivity of brain tissue to oxidative stress that arises from its 
oxygen metabolic rate which is the highest throughout the body, its high 
concentration of unsaturated fatty acids which can be easily modified by free radicals 
and finally by its high level of iron, an element that correlates with injury caused by 
free radicals190. In contrast, the tissue features respectively low amounts of 
antioxidant agents and enzymes190.  
As mentioned in chapter 1.10, MPO moreover catalyzes the oxidation of halides and 
thiocyanate (SCN-), a pseudohalide, to the respective hypohalous acids191 cited by 190 
resulting in “chlorinative stress”190 to the surrounding tissue (see fig. 8). Interestingly, 
these reactions may also occur in the brain and are associated with several 
neurological diseases, as for example Parkinson’s disease, Alzheimer’s disease, 
Multiple Sclerosis and cerebral ischemia190.   
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Figure	8:	Overview on interactions between different redox-systems producing free radicals 
that can affect the host tissue by either nitrative, chlorinative or oxidative stress.  
“In conclusion, chlorinative stress appears to be the centered mediator of 
neurodegeneration. Blue arrows represent the most likely route for oxidants production in 
diseased brains.” 190 Figure obtained from: 190 
Indeed, MPO has been detected in microglia192, which are macrophages located at 
the central nervous system. Especially in brains derived from patients suffering from 
Alzheimer’s disease, MPO has been shown in activated microglia, associated with 
hippocampal cells as well as with plaques and tangles193 cited by 186.  
Due to unequal empirical findings, proposing either a protective or a detrimental role 
of the MPO [-463A] allele, a possible contribution of MPO -463G>A genotype to the 
development of cognitive decline is discussed more controversially (for detailed 
review see 186). According to Pope et al., these unsteady results basically come from  
statistical bias including different selection criteria, lack of statistical power as well as 
an unequal gender distribution between groups194 cited by 186. As an example, the 
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author mentioned a Finnish study postulating, that homozygous male carriers of the 
MPO [-463A] allele show a decreased life expectancy195 cited by 186. However, this 
suggests a depletion of this allele in male persons of advanced age indicating a 
possible source of statistical bias, for example if ages differ between groups186.  
However, increased cognitive impairment with the MPO [-463A] allele, which again is 
associated with decreased MPO expression, lead one to assume that this occurs 
“within a more systemic aspect of the disease” 186.  
In case of Alzheimer’s disease, neurofibrillary tangles and amyloid plaques are highly 
affine for negatively charged glycoproteins. Additionally, reduced MPO activity may 
again lead to reduced defense mechanisms against oxidative stress. Hence, any 
available MPO could affect tissue of homozygous carriers of the MPO [-463A] allele 
more heavily, what subsequently leads to promotion of cognitive decline196 cited by186.  
    
1.13. EXERCISING,	OXIDATIVE	STRESS	AND	COGNITIVE	DECLINE	
As mentioned before, oxidative stress refers to a state of high concentrations of 
reactive oxygen species that can modify physiological components as for example 
proteins and lipids. Because the production of reactive oxygen species increases 
with O2 intake, physical exercising results in an up to 20-fold elevation of these 
radicals197 cited by 198, suggesting that training increases oxidative stress. 
Nevertheless, different studies lead to different results198.  
Regarding patients suffering from neurodegenerative diseases, Bloomer et al. 
showed that patients with Parkinsons’ Disease performing short-term resistance 
training showed reduced oxidative stress markers malon dialdehyde (15%) and H2O2 
(16%)199.  
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However, it can be assumed that chronic exercise may cause increased resistance 
to reactive species, whereas acute, strenuous exercise may increase oxidative 
stress200-204 cited by 198. 
In conclusion, the effect of physical exercise on cognitive function still merits further 
investigation. In a recent meta-analysis of11 randomized controlled trials, Angevaren 
et al. reported that it is still unknown, whether cognitive functions after physical 
exercise may improve due to enhanced cardiorespiratory fitness or due to other 
factors that are not yet elucidated205.  
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2. AIMS	AND	HYPOTHESES	
In conclusion, the role of oxidative stress in cognitive decline is not yet completely 
elucidated. Moreover, cognitive functions may also be affected by physical exercising 
that in turn alters the amount of reactive oxygen species. Thus, our aim is to 
investigate the role of myeloperoxidase as a reactive oxygen species producing 
enzyme in exercising elderly people with respect of their cognitive functions, leading 
to the following main hypotheses: 
 Elevated oxidative stress indicated by high myeloperoxidase concentrations 
may correlate with lower success in cognitive tests. This may be due to brain 
damage, atherosclerosis and thrombosis caused by reactive species 187,188 and 
189 cited by 186.	
 Consequently, these alterations may also be visualized via magnetic 
resonance imaging resulting in abnormal findings (gliosis, changes in 
cerebrospinal fluid (CSF) space volume).   	
	
 Reduced MPO levels may in turn lead to reduced defense mechanisms 
against oxidative stress. Hence, even small amounts of myeloperoxidase 
could cause severe damage to brain tissue as reported by 196 cited by186. Thus, 
carriers of the MPO [-463A] allele may be of higher risk regarding impaired 
cognitive functions.	
	
 Preparation for endurance sport events needs constant training. In a first 
phase, the increase of O2 intake will facilitate increased production of reactive 
oxygen species198. Thus, MPO serum concentration may be affected.	
 
 As reported by Vaccarino et al., serum myeloperoxidase is associated with 
major depressive disorder206. Thus, we are expecting an interrelationship 
between MPO levels/genotype and parameters representing subjective well-
being as well as scores reached at self-rating tests assessing depressive 
disorders.   	
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3. METHODS	
3.1. STUDY	DESIGN	
We prospectively enrolled 113 of 130 participants in a longitudinal cohort study 
consisting of 56 athletes, which were either marathon runners or bicyclists and a 
control group of 58 participants, which were matched according to age, sex and 
years of education. Data has been so far collected at baseline; follow-ups are 
planned after five and ten years. Thus, this report is limited to discussion of baseline 
measurements. 
 Athletes had to meet the following study inclusion criteria:  
a) Participation in at least one of the following marathons within the last three 
years: Wachau Half Marathon (21.5 km), Vienna City Marathon (43 km), 
Carinthian Marathon (180 km bicycle) 
b) At least two hours training per week during the recruitment phase 
c) Age over 60 years 
The following criteria lead to exclusion of the study: 
a) Present or past exposure to neurotoxic compounds 
b) If their native language was not German (verbal intelligence tests) 
c) Diseases affecting CNS functions: stroke, multiple sclerosis, brain tumors, 
depression, Alzheimer’s disease, epilepsy, Parkinson’s disease. 
d) Cardiovascular diseases 
e) Chronic alcoholism (>60 g daily intake of ethanol or diagnosed history of 
alcoholism)  
f) Unwillingness to give informed consent 
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 The study design has been reported previously 207. 
Reporting of the study conforms to STROBE208 and the broader EQUATOR 
guidelines209. 
3.2. PARTICIPANT	RECRUITMENT	
Atheletes were recruited at appropriate events with help of the organizers (2008 
Wachau Half Marathon, Vienna City Marathon, Carinthian Marathon) as well as via 
personal contacts. Participants within the control group were recruited via 
advertisements (two in the Austrian Newspaper “Neue Kronenzeitung”, one in the 
Austrian bicyclist journal “Radsport”) as well as via personal contact.   
3.3. ETHICAL	ASPECTS	
The study has been approved by the ethics committee of the Medical University of 
Vienna (EK 401/2005). All participants were informed about the study goals and the 
study protocol by authorized medical personell. Accordingly, all included test persons 
gave written informed consent. Moreover, all medical procedures conformed to 
institutional guidelines. 
3.4. COGNITIVE	TESTING	
Several neurophysiological tests were conducted in order to assess different 
cognitive functions (see table 2 for a detailed list). 
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Cognitive testing methods  
Neurophysiological 
functions 
Neurophysiological Test Task
Screening of Global 
Cognitive Functions 
MMSE (VNTB/CERAD) Screening of global cognitive functions 
(orientation, memory, attention, 
language, visuo-construction and numeracy) 
Clock Drawing Test 
(VNTB/CERAD)  
Drawing a clock, putting in all the numbers 
and setting hands at 10 past 11 
Premorbid Intelligence WST (VNTB) Vocabulary Test 
Visuo-Construction  
 
TEVK (VNTB) Clock-Drawing, Cube-copying, Copying a 
geometrical figure 
Copying Figures (CERAD) Copying four geometrical figures 
Attention  
 
AKT (VNTB) Selective cancellation of semi-circles 
WAIS-R Subtest: Digit 
Symbol Subtest (VNTB) 
Transformation of digits into corresponding 
symbols 
 
C.I. Symbol Counting Task 
(VNTB) 
Counting quadrates and distinguishing them 
from other symbols 
 
TMT-A (VNTB, CERAD) Connecting numbers from 1 to 25 
 
NAI Stroop Test (VNTB) Naming colors facing the challenge that the 
color of the ink doesn’t match 
the name of the color 
C.I. Interference Test 
(VNTB)  
Substitution of A into B and B into A 
Language Functions  
 
Semantic Verbal Fluency 
Test (VNTB, CERAD) 
Naming words from a category within 1 min 
(animals, supermarket items, tools) 
Phonemic Verbal Fluency 
Test (VNTB, CERAD) 
Naming words beginning with a specific letter 
within 1 min (b, f, l, s) 
 
mBNT (VNTB, CERAD) Naming objects from line drawings 
Memory 
Verbal Memory 
 
Verbal Memory Immediate 
Recall (VNTB, CERAD) 
Recalling a wordlist after first presentation 
Verbal Memory Total Recall 
(VNTB, CERAD) 
Recalling a wordlist after repeated 
presentation (5 resp. 3 times) 
 
Verbal Memory Delayed 
Recall (VNTB, CERAD) 
Recalling a wordlist after 10–30 min 
 
Verbal Memory Recognition 
(VNTB, CERAD) 
Distinction between learnt words and 
distracting words 
	
40	
	
Figural Memory Figural Memory Total Recall 
(CERAD) 
Recalling geometrical figures after 10–15 
min 
Executive Functions 
Planning  NAI Maze Test (VNTB) Finding the right way out of a maze as fast 
as possible 
Shifting and Task 
Switching Capabilities 
 
TMT-B (regarding TMT-A) 
(VNTB, CERAD) 
Alternating connection of numbers and 
letters (1, A, 2, B…) 
Nonverbal Fluency Five Point Test (VNTB) Drawing different figures in connecting points 
with straight lines 
Semantic Verbal 
Fluency 
 
Semantic Verbal Fluency 
Test (VNTB, CERAD) 
Naming words from a category within 1 
minute (animals, supermarket items, 
tools) 
Phonemic Verbal 
Fluency 
 
Phonemic Verbal Fluency 
Test (VNTB, CERAD) 
Naming words beginning with a specific letter 
within 1 min (b, f, l, s) 
Interference Capability  
 
NAI Stroop Test (VNTB) Naming colors facing the challenge that the 
color of the ink doesn’t match the 
name of the color 
 C.I. Interference Test 
(VNTB)  
Substitution of A into B and B into A 
			
Table	2: “AKT Alters-Konzentrations-Test, C.I. Cerebral Insufficiency Test, CERAD 
Consortium to Establish a Registry for Alzheimer‘s Disease, mBNT modified Boston Naming 
Test, MMSE Mini Mental State Examination, NAI Nürnberger-Alters-Inventar, TEVK Test zur 
Erfassung der Visuokonstruktion, TMT-A Trail Making Test Version A, TMT-B Trail Making 
Test Version B, VNTB Vienna Neuropsychological Test Battery, VSRT Verbal Selective 
Reminding Test, WAIS-R Wechsler Adult Intelligence Scale – Revised, WST Wortschatztest.”. 
(Table with slight modifications reprinted from 207)	
 
Even mild cognitive impairment could be registered210-213 cited by 207 by classification of 
cognitive functions that are commonly affected by dementia (visuo-construction, 
concentration and attention, language, memory, executive functions) using the 
Vienna Neuropsychological Test Battery212,213  and the testing recommendations 
mentioned by the Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD)214 respectively.  
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The testing procedures for each participant took approximately 90-110 minutes, 
starting with the Mini Mental State Examination (MMSE)215 and the Clock Drawing 
Test216 for assessment of global cognitive functions, followed by drawing and copying 
tasks according to Test zur Erfassung der Visuokonstruktion (TEVK)217 and the 
CERAD subtest Copying. For evaluation of attention, the following 
neuropsychological tests were applied: Alters-Konzentrationstest (AKT)218, Wechsler 
Adult Intelligence Scale (WAIS-R) subtest Digit Symbol Subtest219, Cerebral 
Insufficiency Test (C.I.) subtest Symbol Counting Task217, Trail Making Test A220, 
Nürnberger-Alters-Inventar (NAI) subtest Stroop Test221, C.I. subtest Interference 
Test217. Moreover, testing of language functions was conducted using semantic and 
phonemic verbal fluency tests as well as the modified Boston Naming Test (mBNT) 
214. Then, verbal and figural memory was tested by the Austrian version of the 
Memory Assessment Clinics (MAC) Grocery List Selective Reminding Test222 termed 
Verbal Selective Reminding Test (VSRT)217 and the CERAD Wordlist214. Finally, 
executive functions were examined using the NAI subtest Maze Test221, the Trail 
Making Test B220, the Five Point Test223 and again verbal fluency and interference 
tests.  
After this, the participants self-evaluated premorbid intelligence224, subjective 
memory functions, physiological and psychological well-beeing225,226, activites of 
daily life227 and depression228,229 via different self-rating scales and forms, as well as 
positive health practices using the German version of the Personal Lifestyle 
Questionnaire (PLQ)230,231.  
3.5. PREANALYTICAL	PROCEDURES:	SAMPLE	COLLECTION	AND	STORAGE	
Collection of biological material in the framework of the APSOEM-survey was 
conducted by the MedUni Wien Biobank. This facility has been founded in 2007 as a 
research project within the Department for Medical and Chemical Laboratory 
Diagnosis at the General Hospital Vienna. However, the MedUni Wien Biobank has 
so far developed firm expertise in pre-analytic handling of liquid biospecimen such as 
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whole blood, blood serum, blood plasma containing various anticoagulants and urine 
as well as protein and nucleic acids extracted from whole blood or peripheral blood 
mononuclear cells. Currently, the MedUni Wien Biobank arranges pre-analytical and 
analytical procedures for more than 20 particular clinical trials in and outside the 
General Hospital Vienna. Due to establishment of a total quality management of the 
home department including certification to ISO 9001:2008, all procedures occur 
according to Standard Operating Procedures. For this reason, quality and 
comparability of biological samples and compliance with privacy protection 
regulations can be assured at any time. 
For this study, blood serum and whole blood was collected in-house and delivered to 
the Department for Medical and Chemical Laboratory diagnosis via the internal 
sample porter system. There, the samples and the accompanying datasheets 
respectively were digitally registered. GBO Vacuette® serum tubes, 10mL (Greiner 
Bio-One, Kremsmuenster, Austria) were centrifuged for 10 minutes at 3500g and 
room temperature after an hour-long coagulation delay. Then, five aliquots á 400µL 
were stored in 750µL Matrix 2D-barcoded tubes (Thermo Fisher Scientific, Hudson, 
USA) and archived in 96-well latch racks on -80 °C, a standard temperature for long 
time storage of various human body fluids 232,233.  
Whole blood was collected into GBO Vacuette® K2EDTA tubes, 3mL (Greiner Bio-
One, Kremsmuenster, Austria), homogenized by repeated inversion and splitted into 
three aliquots á 500µL, stored in Matrix 2D-barcoded tubes in 96-well latch ratchs at 
-80°C as well. All aliquotation steps were conducted on an Olympus OLA 2500 
sample allocation system (Olympus Deutschland GesmbH, Hamburg, Germany) with 
multiple optical sample identification features, fully automated fluid aliquotation 
robots and simultaneous transfer of sample position data to MOLIS (Sysmex, 
Norderstedt, Germany) laboratory information system (LIMS). Archiving positions 
and corresponding 2D-barcodes of anonymous samples were stored in a Microsoft 
Access database (Microsoft, Redmond, USA), physically divided from LIMS 
containing participant related data. Linkage between these data bases, which is 
necessary for proper sample identification upon retrieval of biomaterial, requires 
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confirmation of the MedUni Wien Biobank Access Request form by the clinical 
conductor of the trial and MedUni Wien Biobank as well 234.  
3.6. MPO	QUANTIFICATION	
Measurement of serum myeloperoxidase concentrations was done by means of 
enzyme-linked immunosorbent assay (ELISA) 235. This method is based on a 
sandwich immunoassay technique, for which antigen specific monoclonal antibodies 
are coated into each well of twelve separate eight-well strips arranged in a 96-well 
reaction plate. After application of the respective antigen, followed by several 
washing steps, a secondary, polyclonal antibody specific for this antigen will be 
added, binding to the pre-bound antigen. After washing again, a substrate solution 
has to be administered. This solution undergoes a chemical reaction catalyzed by a 
functional modification of the secondary antibodies Fc-domain resulting in a change 
in color. This optical transformation is proportional to the respective antigen 
concentration and can then be measured on a photospectrometer and compared to a 
standard curve made from known antigen concentrations. 
In our case, a Quantikine® Human MPO Immunoassay kit (R&D Systmes, Inc., 
Minneapolis, USA) was used 236. For this, a 400µL blood serum aliquot of each 
participant was retrieved from MedUni Wien Biobank storage ressource and brought 
to room temperature. For the following immunoassay, a 50-fold dilution of each 
sample in Calibrator Diluent RD6-57 was prepared as suggested by the 
manufacturer.  
A MPO standard curve was prepared from a MPO standard solution provided with 
the kit yielding the following concentrations: 100ng/mL, 50ng/mL, 25ng/mL, 25ng/mL, 
12.5ng/mL, 6.25ng/mL, 3.12ng/mL and 1.56ng/mL. 
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100µL of each standard and sample, diluted 1:2 with Assay Diluent RD1-62 were 
applied to the pre-coated reaction wells and incubated covered for two hours shaking 
at room temperature. After completely discarding the fluid, four washing steps with 
Wash Buffer (400µL each well) were performed. 200µL of MPO Conjugate, 
containing the secondary, polyclonal antibody, were added to each well. After that, 
the solution was incubated again covered for two hours shaking at room 
temperature. Then, removal of the liquid and subsequent washing was conducted as 
described before. After addition of 200µL of Substrate Solution to each standard and 
sample, a 20 minutes light-protected incubation period at room temperature was 
awaited. Following, the reaction was stopped by administration of 50µL Stop Solution 
resulting in a color shift from blue to yellow. Extinction of standards and samples at 
450nm was measured in a Wallac 1420 Victor2™ Multilabel Counter (Perkin Elmer, 
Waltham, USA) using the Wallac 1420 Victor2™ Workstation V 3.00.0.46 R2 (Perkin 
Elmer) software. 
3.7. MPO	‐463G>A	GENOTYPING	
Genotyping of the MPO -463G>A polymorphism was done by means of real time 
PCR with sequence-specific TaqMan® probes. To evaluate the method, a set of 15 
randomly chosen samples was additionally analyzed by restriction fragment length 
polymorphism analysis. Consequently, equality of each participant’s results gained 
from each method has been assessed.       
3.7.1. DNA	PREPARATION	
DNA was extracted from frozen whole blood semi-automated on a Corbett X-
tractor gene CAS 1820 (Qiagen, Hilden, Germany) using Macherey Nagel 
Nucleospin 96-Blood DNA extraction kits (Macherey Nagel, Dueren, Germany). 
For this, a 500µL aliquot of each participant was thawed and gently 
homogenized. Each 200µL were transferred to a single position of a 96-deep-
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well plate. The whole blood was diluted with 100µL phosphate buffered saline 
(Invitrogen, Paisley, UK) to avoid inefficient DNA isolation due to hyperviscous 
starting material. Subsequently, the deep-well plate was loaded onto the X-
tractor gene and the required amount of reaction buffers provided by the 
Corbett X-tractor gene application software was supplied to the predefined 
slots.  
All of the following steps were conducted by the automatically. Firstly, lysis of 
nucleated blood cells was reached by admixture of 150µL Lysis Solution (Buffer 
BQ1 + Proteinase K, 3+1) followed by a 30 minutes incubation time. 
Afterwards, 400µL of Lysis Buffer (Buffer BQ1 + Ethanol abs., 1+1) had been 
added before incubation for five minutes.  Then the samples were transferred to 
a capture plate containing 96 distinct affinity chromatography columns with a 
DNA-specific solid phase and covered with an overlay of 150µL Buffer B5. A 
15kPa Vacuum was applied for 5 minutes to facilitate migration of DNA to the 
solid phase and enable flow of solvated cell debris to an attached waste 
chamber. After this step, the columns were manually inspected for complete 
aspiration of the cell lysate. In case of insufficient suction, the column material 
was penetrated with a thin pin (to avoid spilling of the buffer during the following 
loading steps because of clogged columns) and the sample’s DNA was isolated 
at one of the following runs. The DNA-binding columns were then washed with 
600µL Buffer BW applying a 20 kPa vacuum for 3 minutes. 
3.7.2. RFLP	ANALYSIS	
After development of a novel method for in-vitro amplification of 
deoxyribonucleic acids within a certain length237, several diagnostic methods 
evolved from this very technique. One of those methods based upon restriction 
fragment length polymorphisms (RFLP)238. This term refers to a setup of two or 
more alleles at a distinct genetic locus that vary in their resistance to a specific 
restriction endonuclease. In our case, transition of guanine to adenine at 
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position -463 of the MPO promoter leads to disruption239 of a 5’-CCGC-3’ 240 
motif.  
However, the intact sequence would act as a recognition site for AciI, a type II 
restriction endonuclease gathered from Arthrobacter citreus. Cleavage of 
double stranded DNA containing a copy of the said sequence would result in 
two distinct helices, both with sticky ends, i. e. each helix with a two base 
extension at the 5’-end resulting from the restriction site. For this, one strand 
has to be cut between the two cytosines of the 5’-CCGC-3’ site, whereas the 
complementary strand undergoes disruption between cytosine and guanine of 
the respective 3’-GGCG-5’ motif (please note the highlighted bases).240 
Again, whether the AciI restriction site is present or not, this solely depends on 
the MPO -463G>A genotype. Conversely, detection of the restriction site thus 
gives information about the underlying genotype. Therefore, a 350 bp 
fragment239 was amplified by means of polymerase chain reaction237.  
However, besides MPO -463G>A, this fragment contained an invariant AciI site 
as an internal control indicating proper digestion239. The possible genotypes 
and their respective pattern of restriction fragments are shown in table 3. 
 
 
 
 
   Possible genotypes  
Genotype G/G G/A A/A 
Fragment length 169, 120, 61 bp 289, 169, 120, 61 bp 289, 61 bp 
 	
Table	3:	The three possible genotypes at position -463 of MPO in an individual featuring two 
copies of chromosome 17 are related to three distinct patterns of restriction fragments, that can 
be visualized by agarose gel electrophoresis239.  
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Polymerase chain reaction was conducted within a total volume 25 µL 
containing the following compounds: 
10 ng template DNA 
12.5 µL DreamTaq™ Green PCR Master Mix (Fermentas GmbH, St. Leon-
Rot, Germany) 
10 pMol primer forward: 5′-CGGTATAGGCACACAATGGTGAG-3’ 239 
10 pMol primer reverse: 5′-GCAATGGTTCAAGCGATTCTTC-3’ 239 (both 
oligonucleotides: VBC Genomics, Vienna, Austria) 
ad 25 µL H2O sterile (Fermentas GmbH) 
Subsequent amplification of the 350 bp-fragment was done applying the 
following conditions239 on an Eppendorf Mastercycler® (Eppendorf AG, 
Hamburg, Germany): 
32 cycles of: 
DNA denaturing step for 30 sec at 94° C 
Primer annealing for 30 sec at 56° C 
Strand extension for 30 sec at 72° C 
After amplification, 5 µL of each PCR product were digested by 15 units AciI 239 
restriction enzyme (New England Biolabs, Schwalbach, Germany) within one 
hour reaction time, thus leading to genotype-specific fragments. These 
fragments were separated on a 2.5 % agarose gel. For this, 1.5 g agarose was 
resolved in 60 mL 1x TBE buffer (gathered from a 10x stock: Promega 
Corporation, Madison, USA) and broiled to boiling point while shaking 
constantly, until agarose was totally solubilized. After the fluid cooled down to a 
tepid temperature, 3 µg of ethidium bromide EtBr (equivalent to 3 µL out of a 
dilution with a concentration of 1ng EtBr per µL ddH2O) were administered due 
to its intercalating properties241 featuring the typical fluorescence spectrum of 
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EtBr-DNA complexes after absorption of ultraviolet radiation242. However, this 
step allows visualization of DNA fragments of different length represented by 
separated fluorescent bands after gel electrophoresis. 
Subsequently, the tepid fluid polymerized after decanting it into a gel 
electrophoresis carriage. Before it, a multidentate comb for generation of self-
contained DNA loading slots has been placed at the upper end of the carriage. 
Then, 10 µL of the digested PCR fragments were loaded each on a separate 
slot. However, on the first slot MspI digested plasmid pBR322 (New England 
Biolabs) was loaded as a size marker.  
Detection and recording of fluorescent EtBr-DNA complex pattern was done 
using a Polaroid MP4+ instant camera system (Polaroid, Minnetonka, USA) and 
Polaroid 667 black and white instant films (Polaroid). 
3.7.3. TAQMAN®	ALLELIC	DISCRIMINATION	
Allelic discrimination using TaqMan® (Applied Biosystems, Rotkreutz, 
Switzerland) technology is based on the so called 5’-nuclease allelic 
discrimination assay243-248 cited by 249. However, the method uses both, 
hybridization combined with 5’-nuclease activity as well as fluorescence 
detection250. TaqMan® allelic discrimination can be done on real-time PCR 
thermocyclers that hence are able to detect changes in fluorescence intensity of 
different fluorophores249.  
For this, a 100 to 150 bp PCR amplicon containing the bialellic SNP has to be 
assigned and the respective flanking primers must be designed. Sequence 
detection itself occurs during annealing phase of the PCR by hybridization of 
sequence specific MGB-probes on the template amplicon. These probes 
consist basically of 13 to 25 nucleotides, whereas the variable base lies at the 
3’-end (but not within the two most 3’ bases). Moreover, the oligonucleotide 
features a 5’-fluorophor. However, its fluorescence is absorbed by a 3’ non 
fluorescent quencher NFQ. Additionally, at the 3’ end a minor grove binder 
MGB facilitates hybridization with the template thus leading to a possible 
reduction of probe length. Each PCR setup contains a set of two probes, each 
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labeled with a discriminative fluorophor, representing either allele of a biallelic 
SNP. During PCR extension phase, Taq polymerase elongates the primer 
located at the 3’-end of a probe-bound template from its 3’- to its 5’-end. 
Thereby, the 5’ nuclease activity of Taq polymerase leads to digestion of the 
probe’s 5’-end and thus releases the fluorophor into solution. That way, its 
fluorescence is no longer absorbed by the still probe-bound NFQ. The increase 
of fluorescence detected in real-time by means of fluorometry thus reflects 
preceding hybridization of either probe 1, probe 2 or in case of heterocygosity 
both of them and therefore indicates the presence of the respective alleles 
within the amplicon. Consequently, a scatter plot can be drawn showing each 
sample’s fluorescence in both fluorophores colors, showing three distinctive 
clusters representing homocygous wild-type, homocygous mutant as well as 
heterocygous donors. 244  
In our case, real-time PCR was conducted in a 384-well format on an ABI 
7900HT Fast Real-time Thermocycler (Appliedbiosystems) in total reaction 
volumes of 5 µL containing the following compounds: 
2.5 µL TaqMan® Genotyping Mastermix (Applied Biosystems) 
2 pMol primer forward: 5'-CTTGGGCTGGTAGTGCTAAATTC-3' 251, 
2 pMol primer reverse: 5'-GTAATTTTTGTATTTTTCCTTAGGCAAGAAGC-3' 
251 (All oligonucleotides: VBC Genomics) 
1.5 pMol probe [-463G]: 5’-VIC- TCCACCCGCCTCAG-MGBNFQ-3’ 251 
1.5 pMol probe [-463A]: 5’-6FAM-TCCACCTGCCTCAG-MGBNFQ-3’ 251 (All 
probes: Applied Biosystems) 
ad 5µL H2O sterile (Fermentas GmbH)  
Samples were genotyped in duplicate. PCR reaction samples without DNA 
have been located on various positions of the 384-well PCR-plate (Applied 
Biosystems) as (cross-) contamination controls. 
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PCR reaction occurred under the following conditions: 
Initial denaturation step for 10 min at 95°C 
40 cycles of: 
DNA denaturing step for 15 sec at 95° C 
Primer annealing/strand extension for 60 sec at 60° C 
Then, a scatter plot of fluorescence intensity was generated using SDS 2.3 
sequence detection software (Applied Biosystems).  
3.8. STATISTICAL	ANALYSES	
Metric data showing a normal distribution is given as mean and standard deviation. 
Other metric data as well as ordinal scaled variables are presented as median and 
interquartile range. Quantitative data is given as counts and percentages. 
Correlations of metric variables featuring a normal distribution as well as point-biseral 
correlations are computed by Pearson’s-tests, monotonous relations between 
elsewise distributed data are assessed using Spearman’s-rank-correlation-test. 
Variables, which means show a normal distribution are compared by one-way 
ANOVA and T-tests. Intergroup-comparison of non-normal distributed metric and 
ordinal scaled data is done using Man-Whitney-U tests (in case of two independent 
groups) and Kruskal-Wallis-tests (in case of more than two independent groups. 
Distributions of qualitative data are compared using Chi-squared-tests. Significances 
must be interpreted one-tailed unless indicated otherwise. 
All computations are accomplished using IBM SPSS Statistics 19.0 (IBM Corp., New 
York, USA). 
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4. RESULTS	
4.1. PARTICIPANT	CHARACTERISTICS	
Participant characteristics  
 Count Percentage 
Female/total participants   
Controls 6/56 10.7% 
Athletes 6/58 10.3% 
   
 Mean SD 
Age   
Controls 65.88 y 4.53 
Athletes 65.96 y 4.74 
Education   
Controls 11.62 y 4 
Athletes 11.07 y 4.08 
   
 Median IQR 
Serum MPO level   
Controls 890.89 ng/mL 616.25 ng/mL 
Athletes 902.6 ng/mL 640.79 ng/mL 
Male participants 903.4 ng/mL 656.92 ng/mL 
Female 
participants 
674.45 ng/mL 609.51 ng/mL 
   
 Count Percentage MPO Median MPO IQR 
MPO-463G>A Genotype     
G/G 70 61.9% 915.68 ng/mL 616.15 ng/mL 
G/A 38 33.6% 
A/A 5 4.4% 585.5 ng/mL 210.95 ng/mL 
		
Table	4:	Overview	on	participant	characteristics	
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We included 56 marathon runners or bicyclists and 58 participants within the control 
group, of which 50(athletes)/52(controls) were of male sex. The mean age of the 
athlete group was 65.96 years (SD=4.74) compared to 65.88 years (SD=4.53) in the 
control group. Athletes experienced education for 11.07 years (SD=4.08), control 
participants for 11.62 years (SD=4.0).  MPO serum levels (athletes: median=902.6 
ng/mL, IQR=640.79 ng/mL; controls: median=890.89 ng/mL, IQR=616.25) did not 
differ significantly between groups    (two-sided p=0.93).  
There was no statistically intergroup difference in MPO -463G>A genotype 
frequencies (athletes: MPO[-463G]/MPO[-463G]=61.8%, MPO[-463G]/MPO[-
463A]=34.5 %, MPO[-463A]/MPO[-463A]=3.6 %; controls: MPO[-463G]/MPO[-
463G]=62.1%, MPO[-463G]/MPO[-463A]=32.8 %, MPO[-463A]/MPO[-463A]=5.2 %, 
p=0.92). However, genotype frequencies were in Hardy-Weinberg-equilibrium in both 
groups (athletes: Chi-squared=0.109, p=0.74; controls: Chi-squared=0.056, p=0.81). 
Expectedly, serum MPO levels were substantially lower in MPO[-463A] homozygous 
participants than in persons with heterozygous or MPO[-463G] homozygous 
genotype (median=585.5 ng/mL, IQR=210.95 ng/mL, compared to median=915.68 
ng/mL, IQR=616.15 ng/mL, p<0.01). 
MPO plasma levels were significantly higher in male (median=903.4 ng/mL, 
IQR=656.92 ng/mL) than in female participants (median=674.45 ng/mL, IQR=609.51 
ng/mL, p<0.05). MPO-463G>A Genotype distribution in male participants (MPO-
463[G]/MPO-463[G]=59.8%, MPO-463[G]/MPO-463[A]=36.3 %, MPO-463[A]/MPO-
463[A]=3.9 %) was not statistically different from that in female persons (MPO[-
463G]/MPO[-463G]=81.8%, MPO[-463G]/MPO[-463A]=9.1 %, MPO[-463A]/MPO[-
463A]=39.1 %, two-sided p=0.17).   
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Figure	9:	Serum	Myeloperoxidase	level	dependent	from	sex	(A),	athleticism	(C) and	MPO‐463G>A	genotype	(E).	Man‐
Whitney‐U	tests	have	been	performed	for	comparison	of	serum	MPO	levels	in	male	and	female	(B)/control	
participants	and	athletes	(D)/genotype	(F),	data	is	presented	as	mean	and	95	%	CI.			
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4.2. MYELOPEROXIDASE	AND	COGNITIVE	TESTS	
Please notice that associations between variables showing a normal distribution are 
given as Spearman’s r, whereas correlations between variables with other 
distributions are presented as Spearman’s ρ. MPO serum levels negatively correlate 
with scores (1-10) from Clock Drawing tests (ρ=-0.2, p<0.05). In a partial correlation 
analysis with WST_IQ score, age and sex as control variables, this association 
persisted in the total study population (ρ =- 0.214, p<0.05) as well as in the control 
group (ρ=-0.328, p<0.01), but not in athletes. Moreover, athletes with higher serum 
MPO take longer to finish the NAI maze test (r=0.25, p<0.05). Keeping said control 
variables constant, the result persisted (r=0.253, p<0.05). Results in the control 
group did not reach significance. However, there was no association between MPO 
level and errors during NAI maze test at all. Accordingly, serum MPO levels did also 
show a significant partial correlation with the time it took participants to finish Trail 
Making Test B (ρ=0.165, p<0.05) as well as with the ratio [time for Trail Making Test 
B]/[time for Trail Making Test A] (ρ=0.213, p<0.05). Group-dependently, only athletes 
showed an association of MPO levels at partial correlation analysis with Trail Making 
Test ratio (r=0.391, p<0.01) and Trail Making Test B (r=0.194, p<0.05).  
Interestingly, participants of the control group with higher serum MPO showed less 
perseverations when they were told to enumerate words starting with the letter “L” at 
phonemic fluency tests (r=-0.23, p<0.05). However, these findings did neither show 
for athletes at bivariate correlation, nor for both groups after partial correlations (said 
control variables). Furthermore, in MPO[-463A] homozygotes showed a trend for 
lower WST-IQ (p=0.054).  
There was no link between cognitive test scores and MPO[-463A]/MPO[-463A] 
genotype except for a higher amount of perseverations at semantic (Z=-2.45, two-
sided p<0.05) and phonemic fluency tests starting with the letter “l” (Z=-2.24, two-
sided p<0.05) in the control group.  
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4.3. MYELOPEROXIDASE	AND	BRAIN	IMAGING	
Participants with increased cerebrospinal fluid space volume featured elevated 
serum MPO levels (median 1039.8 ng/mL, IQR=628.98 ng/mL compared to 
median=835.3 ng/mL, SD=634.6, p<0.05), unless these findings lost statistical 
significance in group-wise analysis, although there was a trend for higher serum 
MPO levels in athletes with CSF space accentuation (p=0.06 compared to p=0.19 in 
the control group). In detail, athletes with serum MPO levels >675 ng/mL were more 
likely to develop CSF space accentuation (20% compared to 45% in participants with 
lower MPO levels, p<0.05) with a relative risk (RR) of 1.33 (95%CI: 0.98 – 1.8).  
Furthermore, study participants with subcortical glial modifications had higher serum 
MPO levels (median=924.06 ng/mL, IQR=862.55 ng/mL) than participants with glial 
modifications within the central medullary layer (median=746.05 ng/mL, IQR=568.84 
ng/mL, p<0.05).    
There was no association between MPO-463G>A genotype and pathological findings 
from MR-imaging.  
	
4.4. MYELOPEROXIDASE	AND	SUBJECTIVE	WELL‐BEING	
Interestingly, we found a statistical association between serum MPO levels, and 
scores from self-rating questionnaires assessing parameters of subjective well-being. 
Hence, self-ratings regarding “overall health perception” correlated with serum MPO 
in athletes by r=-0.23, p<0.05. In contrast, there were correlations/trends between 
serum MPO and “vitality” (ρ=-0.23, p<0.05), “physical pain” (ρ=-0.21, p=0.056), 
“overall health perception” (ρ=-0.2, p=0.07) and “mental well-being” (ρ=-0.2, p=0.07) 
in the control group.  
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Consequently, participants homozygous for the MPO[-463A] awarded significantly 
more points regarding their “vitality” (Z=-1.65, p<0.05), “mental well-being” (Z=-1.95, 
p<0.05) and “mental scale” (Z=- 1.87, p<0.05).   
Moreover, athletes with high serum MPO (>675 ng/mL) scored significantly higher in 
Geriatric Depression Scale self-ratings (p<0.05), however, none of the marathon 
runners reached the test range indicating mild (10-19) or severe (20-30) depression. 
Furthermore, there is also trend for higher scores in MPO[-463G] homozygotes 
compared to MPO[-463A] homozygous study participants (Z=-1.481, p=0.088). 
Interestingly, correlation coefficients (Geriatric Depression Scale score X MPO level) 
solely reached significance in participants heterozygous for the MPO[-463A] allele 
(ρ=0.31, p<0.05). In a groupwise comparison, no significant results could be 
computed. Nevertheless, there was a trend for an association of serum MPO and 
Geriatric Depression Scale Score in athletic MPO[-463A]-carriers (ρ=0.33, p=0.086). 
Figure 10: Distribution of Geriatric Depression Scale scores has been compared between athletes with high 
(>675) and low (<675 ng/mL) serum MPO by Man‐Whitney‐U test (A). The same was done for MPO[‐463G] and 
MPO[‐463A] homozygotes (B).  Scores of the Geriatric Depression Scale can be interpreted as follows: 0‐9=no 
depressive disorder indicated, 10‐19=mild depressive disorder indicated, 20‐30=major depressive disorder 
indicated. Numbers in brackets indicate absolute counts.  
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5. DISCUSSION	
5.1. MYELOPEROXIDASE	AND	PATIENT	CHARACTERISTICS	
Myeloperoxidase levels did not differ significantly in atheltes and controls. A study 
conducted by Garatachea et al.,252 MPO levels of kayakers at different stages of 
training have been measured.  Interestingly, the investigators found no significant 
associations between MPO concentrations and intensity of the training. Our findings 
moreover conform to previous publications, which indicate, that plasma MPO levels 
may be elevated immediately after exhaustive training, but return to their previous 
concentrations at rest253-255.  
	
5.2. MYELOPEROXIDASE	AND	COGNITIVE	TESTS	
Interactions between MPO serum level and cognitive test outcome could be shown 
for assessments of global cognitive functions, as well as for executive functions. On 
the one hand, we found significant correlations between plasma MPO and worse 
performance in clock drawing test, NAI maze test and Trail-Making test B. On the 
other hand, participants homozygous for the MPO[-463A] allele, which thus feature 
low serum MPO were more likely to repeat said words when they were asked to 
mention as many words as possible starting with the letter “L” (phonemic fluency) or 
belonging to a certain group (semantic fluency) within one minute of time. 
As mentioned before, oxidative stress may contribute to cognitive impairment by 
either increased atherosclerosis and thrombosis187,188  or selective brain damage189. 
Moreover, there is evidence that strenuous exercising in contrast to moderate 
physical activity enhances production of reactive oxygen species and thus causes 
oxidative stress198. This hypothesis has been supported by findings from animal 
experiments, as mice showed worse performances in tests of cognitive function after 
	
58	
	
exhaustive exercising256. Consequently, athletes with higher basal MPO levels may 
experience harmful MPO concentrations after intense exercising. Indeed, our 
findings support this hypothesis. Athletes with lower serum MPO scored better in NAI 
maze test as well as in Trail-Making test B/A ratio and in Trail Making Test B, all of 
them representing executive functions (planning and task shifting capabilities 
respectively). There again, partial correlations between the clock drawing test 
assessing global cognitive functions could only be evinced significantly in the control 
group, indicating that global cognitive functions could be protected by endurance 
exercising. Since assessment of global cognitive function includes analysis of a 
variety of different mechanisms and aspects of cognition, executive cognitive 
functions represent a specific cognitive domain, which involve development and 
performance of purposive behavior, as well as judgment and abstract thinking257 cited 
by 258. As shown before, executive impairment directly influences instrumental 
activities of daily livingand may thus be a stronger predictor of functional difficulty 
than global cognitive functions257,259,260. 
To the best of our knowledge, a connection between low serum MPO 
level/homozygous MPO[-463A] genotype and increased perseverations in 
semantic/phonemic fluency test has not been reported before. Perseveration scores 
of fluency tests are a sensitive marker for frontal dysfunction261.  Consequently, a 
higher amount of repetitions in A/A homozygous participants could indicate frontal 
dysfunction due to less protective defense mechanisms 196 cited by186.  
5.3. MYELOPEROXIDASE	AND	BRAIN	IMAGING	
As mentioned before, microglia cells, which build up the cell mediated immune 
system of the central nervous system, express moderate amounts of MPO192. Hence, 
myeloperoxidase can leak from activated microglia to the intercellular space. There, 
the enzyme could cause damage to cerebral host tissue via production of ROS.   
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Truly, we could find a statistical association between attenuation of cerebrospinal 
space as a sign of cerebral atrophy and MPO serum levels. However, in groupwise 
partial correlations, these – statistically non-significant – result was more prominent 
in athletes than in control participants (p=0.06 compared to p=0.19). Comparing 
athletes with serum MPO levels <675 ng/mL to athletes with lower MPO 
concentrations, the first had a slightly elevated relative risk (1.33) of developing CSF 
space accentuations. These findings again indicate, that high MPO levels could be 
more detrimental in endurance athletes than in the average population.   
5.4. MYELOPEROXIDASE	AND	SUBJECTIVE	WELL‐BEING	
In our case, Myeloperoxidase levels are associated with self-rating scores regarding 
the state of health and mood. In fact, Vaccarino et al. reported elevated serum MPO 
in patients suffering from major depressive disorder206. This again supports our 
hypothesis, that serum MPO levels are associated with mood and mental disorders. 
Again, we showed a significant association between high Geriatric Depression Scale 
scores and homozygosity for the MPO[-463G] allele. Galecki et al. observed, that the 
MPO[-463G] allele increased the risk of suffering from a depressive disorder by 1.5 
(95% CI: 1.05 – 2.33), whereas the risk for MPO[-463G] homozygous participants 
was increased 1.7-fold (95% CI: 1.09 – 2.79)262. 
Interestingly, the association of serum MPO and Geriatric Depression Scale score is 
significant in carriers of the MPO[-463A] allele, but not in participants homozygous 
for the more common MPO[-463G] allele. This implies that there may be a loss of 
defense mechanisms due to decreased myeloperoxidase expression as mentioned 
before. In this case, higher amounts of myeloperoxidase could cause more severe 
damage than in tissue featuring more adequate host protection against oxidative 
stress196 cited by186. 
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5.5. LIMITATIONS	AND	BENEFITS	OF	THIS	STUDY	
However, this is not a final report of the APSOEM-trial. Much more it must be seen 
as a status record of what we so far learnt about what myeloperoxidase serum level 
and genotype may contribute to cognitive function, alternations in the physical 
constitution of the brain, as well as subjective well-being and mood state in elderly 
marathon runners and bicyclist. Having passed a first and second follow-up after five 
and ten years respectively, we will be able to study time dependent variables. Then it 
will be possible to investigate, whether there is a difference, how high serum MPO 
influences the onset time of more manifest cognitive decline, brain atrophy and 
mental parameters in athletes and non-athletes.  
We have to disclose as a limitation of our study, that there are several discrepancies 
regarding the recommended biomaterial for MPO level measurement. Although the 
manufacturer’s protocol of the used ELISA-kit suggests cell culture supernates, cell 
lysates, plasma, saliva, urine, human milk and of course also serum as adequate 
material236, Shih et al.263 refer to Chang et al.264, when they reported, that blood 
coagulation MPO is spilled by leukocytes and should thus not be used for 
measurement of myeloperoxidase concentrations. By this mechanism, MPO 
concentrations increase with time until separation of cells and serum. Nevertheless, 
they stated an acceptable correlation between their recommended material EDTA-
anticoagulated plasma and serum (r=0.821, slope=4.14, intercept=33.29). Again it 
should be said, that because of standardized preanalytical procedures including 
throughput-time, processing and storage of samples, the disadvantages of the used 
material might be mitigated to the greatest possible extend.  
Another limitation affecting computations on possible genotype-dependent variables 
is the relative small sample count resulting in a small number of participants being 
homozygous for the minor allele. Thus, associations of the MPO[-463A]/MPO[-463A] 
genotype should be interpreted with caution. Assuming that we wanted to estimate 
the required sample size for calculation of differences in Mann-Whitney-U-tests with 
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a large effect size (d=0.5) presuming a statistical power of 0.8 (1 – β-error) and an α-
error of 0.05, the statistics tool G*Power265,266 would suggest to analyze 28           
MPO[-463A] homozygous participants which means that we had to collect at least 
648 persons (presuming 4% of the study population homozygous for the minor 
allele).   
Again, we are aware that because of statistical correlation, although significant, 
causal association of different variables cannot be assumed. However, by partial 
correlation, potential influences of other variables could be kept constant. After follow 
up, it will be possible to assess by multivariate regression analysis, whether 
myeloperoxidase serum level and genotype respectively could be used as an 
independent risk marker for cognitive decline in elderly sportspeople.  
To the best of our knowledge, this is the first prospective cohort study on the effect of 
myeloperoxidase and thus oxidative stress on cognitive function in a cohort of elderly 
endurance athletes.  
Concludingly, we suggest that myeloperoxidase affects executive function, 
morphological cerebral degeneration and subjective well-being dependent from 
physical activity and MPO-463G>A genotype as well. However, there is only little 
knowledge about the underlying mechanisms, which thus still have to be elucidated. 
 
 
 
	
62	
	
6. REFERENCES	
1. Agner K. Verdoperoxidase. A ferment isolated from leucocytes. Acta Chem 
Scand 1941;2:1-62. 
2. van der Veen BS, de Winther MP, Heeringa P. Myeloperoxidase: molecular 
mechanisms of action and their relevance to human health and disease. Antioxid 
Redox Signal 2009;11:2899-937. 
3. Agner K. Detoxicating effect of verdoperoxidase on toxins. Nature 
1947;159:271. 
4. Maehly AC. [142] Myeloperoxidase. In: Methods in Enzymology: Academic 
Press; 1955:794-801. 
5. Schultz J. Myeloperoxidase. Ann N Y Acad Sci 1958;75:22-30. 
6. Furtmüller PG, Zederbauer M, Jantschko W, Helm J, Bogner M, Jakopitsch C, 
Obinger C. Active site structure and catalytic mechanisms of human peroxidases. 
Archives of Biochemistry and Biophysics 2006;445:199-213. 
7. O'Brien PJ. Peroxidases. Chemico-Biological Interactions 2000;129:113-39. 
8. Ueda T, Sakamaki K, Kuroki T, Yano I, Nagata S. Molecular Cloning and 
Characterization of the Chromosomal Gene for Human Lactoperoxidase. European 
Journal of Biochemistry 1997;243:32-41. 
9. Entrez Gene: gene-centered information at NCBI. 2005. (Accessed Database 
issue, 33, at http://view.ncbi.nlm.nih.gov/pubmed/15608257.) 
10. Database of Single Nucleotide Polymorphisms (dbSNP). National Center for 
Biotechnology Information - National Library of Medicine. dbSNP 
accession:{ss3285182}, (dbSNP Build ID: {37.1}). (Accessed 27.03.2011, at 
http://www.ncbi.nlm.nih.gov/SNP/.) 
11. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An 
Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid 
hormone-retinoic acid response element. J Biol Chem 1996;271:14412-20. 
12. Austin GE, Lam L, Zaki SR, Chan WC, Hodge T, Hou J, Swan D, Zhang W, 
Racine M, Whitsett C, et al. Sequence comparison of putative regulatory DNA of the 
5' flanking region of the myeloperoxidase gene in normal and leukemic bone marrow 
cells. Leukemia 1993;7:1445-50. 
	
63	
	
13. Hashinaka K, Nishio C, Hur SJ, Sakiyama F, Tsunasawa S, Yamada M. 
Multiple species of myeloperoxidase messenger RNAs produced by alternative 
splicing and differential polyadenylation. Biochemistry 1988;27:5906-14. 
14. Britten RJ, Baron WF, Stout DB, Davidson EH. Sources and evolution of 
human Alu repeated sequences. Proc Natl Acad Sci U S A 1988;85:4770-4. 
15. Deininger PL, Batzer MA, Hutchison CA, 3rd, Edgell MH. Master genes in 
mammalian repetitive DNA amplification. Trends Genet 1992;8:307-11. 
16. Brini AT, Lee GM, Kinet JP. Involvement of Alu sequences in the cell-specific 
regulation of transcription of the gamma chain of Fc and T cell receptors. J Biol 
Chem 1993;268:1355-61. 
17. Hambor JE, Mennone J, Coon ME, Hanke JH, Kavathas P. Identification and 
characterization of an Alu-containing, T-cell-specific enhancer located in the last 
intron of the human CD8 alpha gene. Mol Cell Biol 1993;13:7056-70. 
18. Hewitt SM, Fraizer GC, Saunders GF. Transcriptional silencer of the Wilms' 
tumor gene WT1 contains an Alu repeat. J Biol Chem 1995;270:17908-12. 
19. Norris J, Fan D, Aleman C, Marks JR, Futreal PA, Wiseman RW, Iglehart JD, 
Deininger PL, McDonnell DP. Identification of a new subclass of Alu DNA repeats 
which can function as estrogen receptor-dependent transcriptional enhancers. J Biol 
Chem 1995;270:22777-82. 
20. Saffer JD, Thurston SJ. A negative regulatory element with properties similar 
to those of enhancers is contained within an Alu sequence. Mol Cell Biol 1989;9:355-
64. 
21. Vansant G, Reynolds WF. The consensus sequence of a major Alu subfamily 
contains a functional retinoic acid response element. Proc Natl Acad Sci U S A 
1995;92:8229-33. 
22. Beato M. Gene regulation by steroid hormones. Cell 1989;56:335-44. 
23. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 
1988;240:889-95. 
24. Leid M, Kastner P, Chambon P. Multiplicity generates diversity in the retinoic 
acid signalling pathways. Trends Biochem Sci 1992;17:427-33. 
25. Pfahl M, Apfel R, Bendik I, Fanjul A, Graupner G, Lee MO, La-Vista N, Lu XP, 
Piedrafita J, Ortiz MA, et al. Nuclear retinoid receptors and their mechanism of 
action. Vitam Horm 1994;49:327-82. 
	
64	
	
26. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM. Retinoid X receptor 
interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 
signalling. Nature 1992;355:446-9. 
27. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence 
of 9-cis retinoic acid and peroxisome proliferator signalling pathways through 
heterodimer formation of their receptors. Nature 1992;358:771-4. 
28. Piedrafita FJ, Pfahl M. Thyroid hormone receptors. In: Baeuerle PA, ed. 
Inducible Gene Expression: Hormonal signals Progress in gene expression. Boston: 
Birkhauser; 1994:157-85. 
29. Zhang XK, Hoffmann B, Tran PB, Graupner G, Pfahl M. Retinoid X receptor is 
an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature 
1992;355:441-6. 
30. Zhang XK, Kahl M. Regulation of retinoid and thyroid hormone action through 
homodimeric and heterodimeric receptors. Trends Endocrinol Metab 1993;4:156-62. 
31. Kurokawa R, Yu VC, Naar A, Kyakumoto S, Han Z, Silverman S, Rosenfeld 
MG, Glass CK. Differential orientations of the DNA-binding domain and carboxy-
terminal dimerization interface regulate binding site selection by nuclear receptor 
heterodimers. Genes Dev 1993;7:1423-35. 
32. Perlmann T, Rangarajan PN, Umesono K, Evans RM. Determinants for 
selective RAR and TR recognition of direct repeat HREs. Genes Dev 1993;7:1411-
22. 
33. Umesono K, Murakami KK, Thompson CC, Evans RM. Direct repeats as 
selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 
receptors. Cell 1991;65:1255-66. 
34. Kadonaga JT, Carner KR, Masiarz FR, Tjian R. Isolation of cDNA encoding 
transcription factor Sp1 and functional analysis of the DNA binding domain. Cell 
1987;51:1079-90. 
35. Resendes KK, Rosmarin AG. Sp1 control of gene expression in myeloid cells. 
Crit Rev Eukaryot Gene Expr 2004;14:171-81. 
36. Bouwman P, Philipsen S. Regulation of the activity of Sp1-related transcription 
factors. Mol Cell Endocrinol 2002;195:27-38. 
	
65	
	
37. Cowland JB, Borregaard N. The individual regulation of granule protein mRNA 
levels during neutrophil maturation explains the heterogeneity of neutrophil granules. 
Journal of Leukocyte Biology 1999;66:989-95. 
38. Chatta GS, Price TH, Allen RC, Dale DC. Effects of in vivo recombinant 
methionyl human granulocyte colony- stimulating factor on the neutrophil response 
and peripheral blood colony-forming cells in healthy young and elderly adult 
volunteers. Blood 1994;84:2923-9. 
39. Dale DC, Liles WC, Llewellyn C, Price TH. Effects of granulocyte-macrophage 
colony-stimulating factor (GM-CSF) on neutrophil kinetics and function in normal 
human volunteers. Am J Hematol 1998;57:7-15. 
40. Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. 
Blood 2008;112:935-45. 
41. Cartwright GE, Athens JW, Wintrobe MM. THE KINETICS OF 
GRANULOPOIESIS IN NORMAL MAN. Blood 1964;24:780-803. 
42. Fehr J, Grossmann H-C. Disparity between circulating and marginated 
neutrophils: Evidence from studies on the granulocyte alkaline phosphatase, a 
marker of cell maturity. American Journal of Hematology 1979;7:369-79. 
43. Ehrlich P, ed. Gesammelte Arbeiten zur Immunitätsforschung. Berlin: A. 
Hirschwald; 1904. 
44. Metchnikov I. Über die Beziehung der Phagocyten zu Milzbrandbacillen. Arch 
Pathol Anat 1884:502-26. 
45. Chediak M. Nouvelle anomalie leucocytaire de caractere constitutionnel 
familial. Rev Hematol 1952:362-6. 
46. Ackerman GA. The human neutrophilic promyelocyte. A correlated phase and 
electron microscopic study. Z Zellforsch Mikrosk Anat 1971;118:467-81. 
47. Bainton DF, Ullyot JL, Farquhar MG. The development of neutrophilic 
polymorphonuclear leukocytes in human bone marrow. J Exp Med 1971;134:907-34. 
48. Bainton DF, Farquhar MG. Differences in enzyme content of azurophil and 
specific granules of polymorphonuclear leukocytes. I. Histochemical staining of bone 
marrow smears. J Cell Biol 1968;39:286-98. 
49. Bainton DF, Farquhar MG. Differences in enzyme content of azurophil and 
specific granules of polymorphonuclear leukocytes. II. Cytochemistry and electron 
microscopy of bone marrow cells. J Cell Biol 1968;39:299-317. 
	
66	
	
50. Borregaard N, Sorensen OE, Theilgaard-Monch K. Neutrophil granules: a 
library of innate immunity proteins. Trends Immunol 2007;28:340-5. 
51. Le Cabec V, Cowland JB, Calafat J, Borregaard N. Targeting of proteins to 
granule subsets is determined by timing and not by sorting: The specific granule 
protein NGAL is localized to azurophil granules when expressed in HL-60 cells. Proc 
Natl Acad Sci U S A 1996;93:6454-7. 
52. Niemann CU, Abrink M, Pejler G, Fischer RL, Christensen EI, Knight SD, 
Borregaard N. Neutrophil elastase depends on serglycin proteoglycan for localization 
in granules. Blood 2007;109:4478-86. 
53. Selsted ME, Harwig SS, Ganz T, Schilling JW, Lehrer RI. Primary structures of 
three human neutrophil defensins. J Clin Invest 1985;76:1436-9. 
54. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:365-76. 
55. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005;77:598-
625. 
56. Klebanoff SJ. Myeloperoxidase-mediated antimicrobial systems and their role 
in leukocyte function. In: Schultz J, ed. Biochemistry of the Phagocytic Process. 
Amsterdam; 1970:89–110. 
57. Kinchen JM, Ravichandran KS. Phagosome maturation: going through the 
acid test. Nat Rev Mol Cell Biol 2008;9:781-95. 
58. Blander JM, Medzhitov R. On regulation of phagosome maturation and 
antigen presentation. Nat Immunol 2006;7:1029-35. 
59. Deretic V. Autophagosome and phagosome. Methods Mol Biol 2008;445:1-10. 
60. Haas A. The phagosome: compartment with a license to kill. Traffic 
2007;8:311-30. 
61. Steinman RM, Mellman IS, Muller WA, Cohn ZA. Endocytosis and the 
recycling of plasma membrane. J Cell Biol 1983;96:1-27. 
62. Lee WL, Harrison RE, Grinstein S. Phagocytosis by neutrophils. Microbes 
Infect 2003;5:1299-306. 
63. Lee JS, Frevert CW, Matute-Bello G, Wurfel MM, Wong VA, Lin SM, Ruzinski 
J, Mongovin S, Goodman RB, Martin TR. TLR-4 pathway mediates the inflammatory 
response but not bacterial elimination in E. coli pneumonia. Am J Physiol Lung Cell 
Mol Physiol 2005;289:L731-8. 
	
67	
	
64. Leendertse M, Willems RJ, Giebelen IA, van den Pangaart PS, Wiersinga WJ, 
de Vos AF, Florquin S, Bonten MJ, van der Poll T. TLR2-dependent MyD88 signaling 
contributes to early host defense in murine Enterococcus faecium peritonitis. J 
Immunol 2008;180:4865-74. 
65. Stadlbauer V, Mookerjee RP, Wright GA, Davies NA, Jurgens G, Hallstrom S, 
Jalan R. Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in 
alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol 2009;296:G15-22. 
66. Bellocchio S, Moretti S, Perruccio K, Fallarino F, Bozza S, Montagnoli C, 
Mosci P, Lipford GB, Pitzurra L, Romani L. TLRs govern neutrophil activity in 
aspergillosis. J Immunol 2004;173:7406-15. 
67. Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human 
neutrophil function. Blood 2003;102:2660-9. 
68. Beutler B. Innate immunity: an overview. Mol Immunol 2004;40:845-59. 
69. Takeda K, Akira S. Microbial recognition by Toll-like receptors. J Dermatol Sci 
2004;34:73-82. 
70. Parker LC, Whyte MK, Dower SK, Sabroe I. The expression and roles of Toll-
like receptors in the biology of the human neutrophil. J Leukoc Biol 2005;77:886-92. 
71. Hornung V, Barchet W, Schlee M, Hartmann G. RNA recognition via TLR7 
and TLR8. Handb Exp Pharmacol 2008:71-86. 
72. Greenberg S, Grinstein S. Phagocytosis and innate immunity. Curr Opin 
Immunol 2002;14:136-45. 
73. Gatfield J, Pieters J. Essential role for cholesterol in entry of mycobacteria into 
macrophages. Science 2000;288:1647-50. 
74. Peyron P, Bordier C, N'Diaye EN, Maridonneau-Parini I. Nonopsonic 
phagocytosis of Mycobacterium kansasii by human neutrophils depends on 
cholesterol and is mediated by CR3 associated with glycosylphosphatidylinositol-
anchored proteins. J Immunol 2000;165:5186-91. 
75. Shin JS, Gao Z, Abraham SN. Involvement of cellular caveolae in bacterial 
entry into mast cells. Science 2000;289:785-8. 
76. Fitzer-Attas CJ, Lowry M, Crowley MT, Finn AJ, Meng F, DeFranco AL, Lowell 
CA. Fcgamma receptor-mediated phagocytosis in macrophages lacking the Src 
family tyrosine kinases Hck, Fgr, and Lyn. J Exp Med 2000;191:669-82. 
	
68	
	
77. Gresham HD, Dale BM, Potter JW, Chang PW, Vines CM, Lowell CA, 
Lagenaur CF, Willman CL. Negative regulation of phagocytosis in murine 
macrophages by the Src kinase family member, Fgr. J Exp Med 2000;191:515-28. 
78. Crowley MT, Costello PS, Fitzer-Attas CJ, Turner M, Meng F, Lowell C, 
Tybulewicz VL, DeFranco AL. A critical role for Syk in signal transduction and 
phagocytosis mediated by Fcgamma receptors on macrophages. J Exp Med 
1997;186:1027-39. 
79. Kiefer F, Brumell J, Al-Alawi N, Latour S, Cheng A, Veillette A, Grinstein S, 
Pawson T. The Syk protein tyrosine kinase is essential for Fcgamma receptor 
signaling in macrophages and neutrophils. Mol Cell Biol 1998;18:4209-20. 
80. Tridandapani S, Lyden TW, Smith JL, Carter JE, Coggeshall KM, Anderson 
CL. The adapter protein LAT enhances fcgamma receptor-mediated signal 
transduction in myeloid cells. J Biol Chem 2000;275:20480-7. 
81. Bonilla FA, Fujita RM, Pivniouk VI, Chan AC, Geha RS. Adapter proteins SLP-
76 and BLNK both are expressed by murine macrophages and are linked to signaling 
via Fcgamma receptors I and II/III. Proc Natl Acad Sci U S A 2000;97:1725-30. 
82. Kyono WT, de Jong R, Kil Park R, Liu Y, Heisterkamp N, Groffen J, Durden 
DL. Differential Interaction of Crkl with Cbl or C3G, Hef-1, and γ Subunit 
Immunoreceptor Tyrosine-Based Activation Motif in Signaling of Myeloid High Affinity 
Fc Receptor for IgG (FcγRI). The Journal of Immunology 1998;161:5555-63. 
83. Izadi KD, Erdreich-Epstein A, Liu Y, Durden DL. Characterization of Cbl-Nck 
and Nck-Pak1 interactions in myeloid FcgammaRII signaling. Exp Cell Res 
1998;245:330-42. 
84. Coppolino MG, Krause M, Hagendorff P, Monner DA, Trimble W, Grinstein S, 
Wehland J, Sechi AS. Evidence for a molecular complex consisting of Fyb/SLAP, 
SLP-76, Nck, VASP and WASP that links the actin cytoskeleton to Fcgamma 
receptor signalling during phagocytosis. J Cell Sci 2001;114:4307-18. 
85. Botelho RJ, Teruel M, Dierckman R, Anderson R, Wells A, York JD, Meyer T, 
Grinstein S. Localized biphasic changes in phosphatidylinositol-4,5-bisphosphate at 
sites of phagocytosis. J Cell Biol 2000;151:1353-68. 
86. Larsen EC, DiGennaro JA, Saito N, Mehta S, Loegering DJ, Mazurkiewicz JE, 
Lennartz MR. Differential requirement for classic and novel PKC isoforms in 
	
69	
	
respiratory burst and phagocytosis in RAW 264.7 cells. J Immunol 2000;165:2809-
17. 
87. Grinstein S. Imaging signal transduction during phagocytosis: phospholipids, 
surface charge, and electrostatic interactions. Am J Physiol Cell Physiol 
2010;299:C876-81. 
88. Hakoshima T, Shimizu T, Maesaki R. Structural basis of the Rho GTPase 
signaling. J Biochem 2003;134:327-31. 
89. Honda A, Nogami M, Yokozeki T, Yamazaki M, Nakamura H, Watanabe H, 
Kawamoto K, Nakayama K, Morris AJ, Frohman MA, Kanaho Y. Phosphatidylinositol 
4-phosphate 5-kinase alpha is a downstream effector of the small G protein ARF6 in 
membrane ruffle formation. Cell 1999;99:521-32. 
90. Zhang Q, Calafat J, Janssen H, Greenberg S. ARF6 is required for growth 
factor- and rac-mediated membrane ruffling in macrophages at a stage distal to rac 
membrane targeting. Mol Cell Biol 1999;19:8158-68. 
91. Carlier MF, Laurent V, Santolini J, Melki R, Didry D, Xia GX, Hong Y, Chua 
NH, Pantaloni D. Actin depolymerizing factor (ADF/cofilin) enhances the rate of 
filament turnover: implication in actin-based motility. J Cell Biol 1997;136:1307-22. 
92. Rosenblatt J, Agnew BJ, Abe H, Bamburg JR, Mitchison TJ. Xenopus actin 
depolymerizing factor/cofilin (XAC) is responsible for the turnover of actin filaments in 
Listeria monocytogenes tails. J Cell Biol 1997;136:1323-32. 
93. Jutras I, Desjardins M. Phagocytosis: at the crossroads of innate and adaptive 
immunity. Annu Rev Cell Dev Biol 2005;21:511-27. 
94. Desjardins M, Huber LA, Parton RG, Griffiths G. Biogenesis of 
phagolysosomes proceeds through a sequential series of interactions with the 
endocytic apparatus. J Cell Biol 1994;124:677-88. 
95. Pitt A, Mayorga LS, Stahl PD, Schwartz AL. Alterations in the protein 
composition of maturing phagosomes. J Clin Invest 1992;90:1978-83. 
96. Desjardins M, Nzala NN, Corsini R, Rondeau C. Maturation of phagosomes is 
accompanied by changes in their fusion properties and size-selective acquisition of 
solute materials from endosomes. J Cell Sci 1997;110 ( Pt 18):2303-14. 
97. Duclos S, Diez R, Garin J, Papadopoulou B, Descoteaux A, Stenmark H, 
Desjardins M. Rab5 regulates the kiss and run fusion between phagosomes and 
	
70	
	
endosomes and the acquisition of phagosome leishmanicidal properties in RAW 
264.7 macrophages. J Cell Sci 2000;113 Pt 19:3531-41. 
98. Cantalupo G, Alifano P, Roberti V, Bruni CB, Bucci C. Rab-interacting 
lysosomal protein (RILP): the Rab7 effector required for transport to lysosomes. 
EMBO J 2001;20:683-93. 
99. Harrison RE, Bucci C, Vieira OV, Schroer TA, Grinstein S. Phagosomes fuse 
with late endosomes and/or lysosomes by extension of membrane protrusions along 
microtubules: role of Rab7 and RILP. Mol Cell Biol 2003;23:6494-506. 
100. Blocker A, Severin FF, Burkhardt JK, Bingham JB, Yu H, Olivo JC, Schroer 
TA, Hyman AA, Griffiths G. Molecular requirements for bi-directional movement of 
phagosomes along microtubules. J Cell Biol 1997;137:113-29. 
101. Dermine JF, Duclos S, Garin J, St-Louis F, Rea S, Parton RG, Desjardins M. 
Flotillin-1-enriched lipid raft domains accumulate on maturing phagosomes. J Biol 
Chem 2001;276:18507-12. 
102. Vilhardt F, van Deurs B. The phagocyte NADPH oxidase depends on 
cholesterol-enriched membrane microdomains for assembly. EMBO J 2004;23:739-
48. 
103. Shao D, Segal AW, Dekker LV. Lipid rafts determine efficiency of NADPH 
oxidase activation in neutrophils. FEBS Lett 2003;550:101-6. 
104. Vieira OV, Botelho RJ, Rameh L, Brachmann SM, Matsuo T, Davidson HW, 
Schreiber A, Backer JM, Cantley LC, Grinstein S. Distinct roles of class I and class III 
phosphatidylinositol 3-kinases in phagosome formation and maturation. J Cell Biol 
2001;155:19-25. 
105. Brumell JH, Grinstein S. Role of lipid-mediated signal transduction in bacterial 
internalization. Cell Microbiol 2003;5:287-97. 
106. Kanai F, Liu H, Field SJ, Akbary H, Matsuo T, Brown GE, Cantley LC, Yaffe 
MB. The PX domains of p47phox and p40phox bind to lipid products of PI(3)K. Nat 
Cell Biol 2001;3:675-8. 
107. Stenmark H, Aasland R, Driscoll PC. The phosphatidylinositol 3-phosphate-
binding FYVE finger. FEBS Lett 2002;513:77-84. 
108. Vieira OV, Bucci C, Harrison RE, Trimble WS, Lanzetti L, Gruenberg J, 
Schreiber AD, Stahl PD, Grinstein S. Modulation of Rab5 and Rab7 recruitment to 
phagosomes by phosphatidylinositol 3-kinase. Mol Cell Biol 2003;23:2501-14. 
	
71	
	
109. McLaughlin S, Wang J, Gambhir A, Murray D. PIP(2) and proteins: 
interactions, organization, and information flow. Annu Rev Biophys Biomol Struct 
2002;31:151-75. 
110. Furtmuller PG, Burner U, Jantschko W, Regelsberger G, Obinger C. The 
reactivity of myeloperoxidase compound I formed with hypochlorous acid. Redox 
Rep 2000;5:173-8. 
111. Davies MJ, Hawkins CL, Pattison DI, Rees MD. Mammalian heme 
peroxidases: from molecular mechanisms to health implications. Antioxid Redox 
Signal 2008;10:1199-234. 
112. Kettle AJ, Winterbourn CC. Superoxide modulates the activity of 
myeloperoxidase and optimizes the production of hypochlorous acid. Biochem J 
1988;252:529-36. 
113. Kettle AJ, Winterbourn CC. Influence of superoxide on myeloperoxidase 
kinetics measured with a hydrogen peroxide electrode. Biochem J 1989;263:823-8. 
114. Kettle AJ, Winterbourn CC. Superoxide enhances hypochlorous acid 
production by stimulated human neutrophils. Biochim Biophys Acta 1990;1052:379-
85. 
115. Kettle AJ, Winterbourn CC. The influence of superoxide on the production of 
hypochlorous acid by human neutrophils. Free Radic Res Commun 1991;12-13 Pt 
1:47-52. 
116. Marquez LA, Dunford HB. Reaction of compound III of myeloperoxidase with 
ascorbic acid. J Biol Chem 1990;265:6074-8. 
117. Marquez LA, Huang JT, Dunford HB. Spectral and kinetic studies on the 
formation of myeloperoxidase compounds I and II: roles of hydrogen peroxide and 
superoxide. Biochemistry 1994;33:1447-54. 
118. Phelps CF, Antonini E, Giacometti G, Brunori M. The kinetics of oxidation of 
ferroperoxidase by molecular oxygen. A model of a terminal oxidase. Biochem J 
1974;141:265-72. 
119. Wittenberg JB, Noble RW, Wittenberg BA, Antonini E, Brunori M, Wyman J. 
Studies on the equilibria and kinetics of the reactions of peroxidase with ligands. II. 
The reaction of ferroperoxidase with oxygen. J Biol Chem 1967;242:626-34. 
	
72	
	
120. Winterbourn CC, Garcia RC, Segal AW. Production of the superoxide adduct 
of myeloperoxidase (compound III) by stimulated human neutrophils and its reactivity 
with hydrogen peroxide and chloride. Biochem J 1985;228:583-92. 
121. Tamura M, Yamazaki I. Reactions of the oxyform of horseradish peroxidase. J 
Biochem 1972;71:311-9. 
122. Yokota K, Yamazaki I. Reaction of peroxidase with reduced nicotinamide-
adenine dinucleotide and reduced nicotinamide-adenine dinucleotide phosphate. 
Biochim Biophys Acta 1965;105:301-12. 
123. Yokota K, Yamazaki I. THE ACTIVITY OF THE HORSERADISH 
PEROXIDASE COMPOUND 3. Biochem Biophys Res Commun 1965;18:48-53. 
124. Malle E, Furtmuller PG, Sattler W, Obinger C. Myeloperoxidase: a target for 
new drug development? Br J Pharmacol 2007;152:838-54. 
125. Klebanoff SJ. Myeloperoxidase. Proc Assoc Am Physicians 1999;111:383-9. 
126. Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. Curr 
Opin Immunol 2003;15:578-84. 
127. Quinn MT, Gauss KA. Structure and regulation of the neutrophil respiratory 
burst oxidase: comparison with nonphagocyte oxidases. J Leukoc Biol 2004;76:760-
81. 
128. Babior BM. The respiratory burst oxidase and the molecular basis of chronic 
granulomatous disease. Am J Hematol 1991;37:263-6. 
129. Segal AW, Jones OT. Novel cytochrome b system in phagocytic vacuoles of 
human granulocytes. Nature 1978;276:515-7. 
130. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in 
cardiovascular biology and disease. Circ Res 2000;86:494-501. 
131. Sorescu D, Szocs K, Griendling KK. NAD(P)H oxidases and their relevance to 
atherosclerosis. Trends Cardiovasc Med 2001;11:124-31. 
132. Souza HP, Laurindo FR, Ziegelstein RC, Berlowitz CO, Zweier JL. Vascular 
NAD(P)H oxidase is distinct from the phagocytic enzyme and modulates vascular 
reactivity control. Am J Physiol Heart Circ Physiol 2001;280:H658-67. 
133. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, 
Heitzer T, Stasch JP, Griendling KK, Harrison DG, Bohm M, Meinertz T, Munzel T. 
Increased NADH-oxidase-mediated superoxide production in the early stages of 
	
73	
	
atherosclerosis: evidence for involvement of the renin-angiotensin system. 
Circulation 1999;99:2027-33. 
134. Yokoyama M, Inoue N, Kawashima S. Role of the vascular NADH/NADPH 
oxidase system in atherosclerosis. Ann N Y Acad Sci 2000;902:241-7; discussion 7-
8. 
135. Zhang C, Yang J, Jacobs JD, Jennings LK. Interaction of myeloperoxidase 
with vascular NAD(P)H oxidase-derived reactive oxygen species in vasculature: 
implications for vascular diseases. Am J Physiol Heart Circ Physiol 2003;285:H2563-
72. 
136. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, Castro L, 
Lusis AJ, Nauseef WM, White CR, Freeman BA. Myeloperoxidase, a leukocyte-
derived vascular NO oxidase. Science 2002;296:2391-4. 
137. Bokoch GM, Knaus UG. NADPH oxidases: not just for leukocytes anymore! 
Trends Biochem Sci 2003;28:502-8. 
138. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev 
Immunol 2004;4:181-9. 
139. Granger DN, Rutili G, McCord JM. Superoxide radicals in feline intestinal 
ischemia. Gastroenterology 1981;81:22-9. 
140. Whittenbury R. HYDROGEN PEROXIDE FORMATION AND CATALASE 
ACTIVITY IN THE LACTIC ACID BACTERIA. J Gen Microbiol 1964;35:13-26. 
141. Eschenbach DA, Davick PR, Williams BL, Klebanoff SJ, Young-Smith K, 
Critchlow CM, Holmes KK. Prevalence of hydrogen peroxide-producing Lactobacillus 
species in normal women and women with bacterial vaginosis. J Clin Microbiol 
1989;27:251-6. 
142. Gupta K, Stapleton AE, Hooton TM, Roberts PL, Fennell CL, Stamm WE. 
Inverse association of H2O2-producing lactobacilli and vaginal Escherichia coli 
colonization in women with recurrent urinary tract infections. J Infect Dis 
1998;178:446-50. 
143. Winterbourn CC. Biological reactivity and biomarkers of the neutrophil oxidant, 
hypochlorous acid. Toxicology 2002;181-182:223-7. 
144. Hazen SL, Hsu FF, Duffin K, Heinecke JW. Molecular chlorine generated by 
the myeloperoxidase-hydrogen peroxide-chloride system of phagocytes converts low 
	
74	
	
density lipoprotein cholesterol into a family of chlorinated sterols. J Biol Chem 
1996;271:23080-8. 
145. Hazen SL, Hsu FF, Mueller DM, Crowley JR, Heinecke JW. Human 
neutrophils employ chlorine gas as an oxidant during phagocytosis. J Clin Invest 
1996;98:1283-9. 
146. Henderson JP, Byun J, Heinecke JW. Molecular chlorine generated by the 
myeloperoxidase-hydrogen peroxide-chloride system of phagocytes produces 5-
chlorocytosine in bacterial RNA. J Biol Chem 1999;274:33440-8. 
147. Albrich JM, Gilbaugh JH, 3rd, Callahan KB, Hurst JK. Effects of the putative 
neutrophil-generated toxin, hypochlorous acid, on membrane permeability and 
transport systems of Escherichia coli. J Clin Invest 1986;78:177-84. 
148. Barrette WC, Jr., Albrich JM, Hurst JK. Hypochlorous acid-promoted loss of 
metabolic energy in Escherichia coli. Infect Immun 1987;55:2518-25. 
149. Rakita RM, Michel BR, Rosen H. Differential inactivation of Escherichia coli 
membrane dehydrogenases by a myeloperoxidase-mediated antimicrobial system. 
Biochemistry 1990;29:1075-80. 
150. Rosen H, Orman J, Rakita RM, Michel BR, VanDevanter DR. Loss of DNA-
membrane interactions and cessation of DNA synthesis in myeloperoxidase-treated 
Escherichia coli. Proc Natl Acad Sci U S A 1990;87:10048-52. 
151. Hazen SL, d'Avignon A, Anderson MM, Hsu FF, Heinecke JW. Human 
neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to 
oxidize alpha-amino acids to a family of reactive aldehydes. Mechanistic studies 
identifying labile intermediates along the reaction pathway. J Biol Chem 
1998;273:4997-5005. 
152. Hazen SL, Hsu FF, d'Avignon A, Heinecke JW. Human neutrophils employ 
myeloperoxidase to convert alpha-amino acids to a battery of reactive aldehydes: a 
pathway for aldehyde generation at sites of inflammation. Biochemistry 
1998;37:6864-73. 
153. Learn DB, Fried VA, Thomas EL. Taurine and hypotaurine content of human 
leukocytes. J Leukoc Biol 1990;48:174-82. 
154. Soupart P. Free amino acids in blood and urine in the human. In: JT Holden, 
ed. Amino Acid Pools. Amsterdam: Elsevier; 1962:220–62. 
	
75	
	
155. Schuller-Levis GB, Park E. Taurine: new implications for an old amino acid. 
FEMS Microbiol Lett 2003;226:195-202. 
156. Peskin AV, Winterbourn CC. Taurine chloramine is more selective than 
hypochlorous acid at targeting critical cysteines and inactivating creatine kinase and 
glyceraldehyde-3-phosphate dehydrogenase. Free Radic Biol Med 2006;40:45-53. 
157. Klebanoff SJ. Oxygen metabolites from phagocytes. In: Gallin JI, Snyderman 
R, eds. Inflammation: Basic Principles and Clinical Correlates. Philadelphia: Lippinc; 
1999. 
158. Lymar SV, Hurst JK. Role of compartmentation in promoting toxicity of 
leukocyte-generated strong oxidants. Chem Res Toxicol 1995;8:833-40. 
159. Kiryu C, Makiuchi M, Miyazaki J, Fujinaga T, Kakinuma K. Physiological 
production of singlet molecular oxygen in the myeloperoxidase-H2O2-chloride 
system. FEBS Lett 1999;443:154-8. 
160. Babior BM, Takeuchi C, Ruedi J, Gutierrez A, Wentworth P, Jr. Investigating 
antibody-catalyzed ozone generation by human neutrophils. Proc Natl Acad Sci U S 
A 2003;100:3031-4. 
161. Farrell AJ, Blake DR, Palmer RM, Moncada S. Increased concentrations of 
nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in 
rheumatic diseases. Ann Rheum Dis 1992;51:1219-22. 
162. Gaston B, Reilly J, Drazen JM, Fackler J, Ramdev P, Arnelle D, Mullins ME, 
Sugarbaker DJ, Chee C, Singel DJ, et al. Endogenous nitrogen oxides and 
bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci U S A 
1993;90:10957-61. 
163. van der Vliet A, Eiserich JP, Halliwell B, Cross CE. Formation of reactive 
nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential 
additional mechanism of nitric oxide-dependent toxicity. J Biol Chem 1997;272:7617-
25. 
164. Augusto O, Bonini MG, Amanso AM, Linares E, Santos CC, De Menezes SL. 
Nitrogen dioxide and carbonate radical anion: two emerging radicals in biology. Free 
Radic Biol Med 2002;32:841-59. 
165. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, van 
der Vliet A. Formation of nitric oxide-derived inflammatory oxidants by 
myeloperoxidase in neutrophils. Nature 1998;391:393-7. 
	
76	
	
166. Hazen SL, Zhang R, Shen Z, Wu W, Podrez EA, MacPherson JC, Schmitt D, 
Mitra SN, Mukhopadhyay C, Chen Y, Cohen PA, Hoff HF, Abu-Soud HM. Formation 
of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for 
monocyte-mediated protein nitration and lipid peroxidation In vivo. Circ Res 
1999;85:950-8. 
167. Jiang Q, Hurst JK. Relative chlorinating, nitrating, and oxidizing capabilities of 
neutrophils determined with phagocytosable probes. J Biol Chem 1997;272:32767-
72. 
168. Kirsch M, Korth HG, Sustmann R, de Groot H. The pathobiochemistry of 
nitrogen dioxide. Biol Chem 2002;383:389-99. 
169. Schmitt D, Shen Z, Zhang R, Colles SM, Wu W, Salomon RG, Chen Y, 
Chisolm GM, Hazen SL. Leukocytes utilize myeloperoxidase-generated nitrating 
intermediates as physiological catalysts for the generation of biologically active 
oxidized lipids and sterols in serum. Biochemistry 1999;38:16904-15. 
170. Lancaster JR, Jr. Nitroxidative, nitrosative, and nitrative stress: kinetic 
predictions of reactive nitrogen species chemistry under biological conditions. Chem 
Res Toxicol 2006;19:1160-74. 
171. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad 
Sci U S A 2004;101:4003-8. 
172. van der Vliet A, Eiserich JP, Kaur H, Cross CE, Halliwell B. Nitrotyrosine as 
biomarker for reactive nitrogen species. Methods Enzymol 1996;269:175-84. 
173. Heinecke JW, Li W, Daehnke HL, 3rd, Goldstein JA. Dityrosine, a specific 
marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide 
system of human neutrophils and macrophages. J Biol Chem 1993;268:4069-77. 
174. Heinecke JW, Li W, Francis GA, Goldstein JA. Tyrosyl radical generated by 
myeloperoxidase catalyzes the oxidative cross-linking of proteins. J Clin Invest 
1993;91:2866-72. 
175. Winterbourn CC, Pichorner H, Kettle AJ. Myeloperoxidase-dependent 
generation of a tyrosine peroxide by neutrophils. Arch Biochem Biophys 
1997;338:15-21. 
176. Bos AJ, Weening RS, Hamers MN, Wever R, Behrendt H, Roos D. 
Characterization of hereditary partial myeloperoxidase deficiency. J Lab Clin Med 
1982;99:589-600. 
	
77	
	
177. Cramer R, Soranzo MR, Dri P, Rottini GD, Bramezza M, Cirielli S, Patriarca P. 
Incidence of myeloperoxidase deficiency in an area of northern Italy: histochemical, 
biochemical and functional studies. Br J Haematol 1982;51:81-7. 
178. Kitahara M, Eyre HJ, Simonian Y, Atkin CL, Hasstedt SJ. Hereditary 
myeloperoxidase deficiency. Blood 1981;57:888-93. 
179. Larrocha C, Fernandez de Castro M, Fontan G, Viloria A, Fernandez-Chacon 
JL, Jimenez C. Hereditary myeloperoxidase deficiency: study of 12 cases. Scand J 
Haematol 1982;29:389-97. 
180. Parry MF, Root RK, Metcalf JA, Delaney KK, Kaplow LS, Richar WJ. 
Myeloperoxidase deficiency: prevalence and clinical significance. Ann Intern Med 
1981;95:293-301. 
181. Kutter D, Devaquet P, Vanderstocken G, Paulus JM, Marchal V, Gothot A. 
Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ? 
Acta Haematol 2000;104:10-5. 
182. Stasia MJ, Li XJ. Genetics and immunopathology of chronic granulomatous 
disease. Semin Immunopathol 2008;30:209-35. 
183. Klebanoff SJ. Myeloperoxidase: contribution to the microbicidal activity of 
intact leukocytes. Science 1970;169:1095-7. 
184. Plassman BL, Williams JW, Jr., Burke JR, Holsinger T, Benjamin S. 
Systematic review: factors associated with risk for and possible prevention of 
cognitive decline in later life. Ann Intern Med 2010;153:182-93. 
185. Pope SK, Shue VM, Beck C. Will a healthy lifestyle help prevent Alzheimer's 
disease? Annu Rev Public Health 2003;24:111-32. 
186. Pope SK, Kritchevsky SB, Ambrosone C, Yaffe K, Tylavsky F, Simonsick EM, 
Rosano C, Stewart S, Harris T. Myeloperoxidase polymorphism and cognitive decline 
in older adults in the Health, Aging, and Body Composition Study. Am J Epidemiol 
2006;163:1084-90. 
187. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 
1994;344:793-5. 
188. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. 
Ann Neurol 1995;38:357-66. 
189. Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev 
1998;78:547-81. 
	
78	
	
190. Yap YW, Whiteman M, Cheung NS. Chlorinative stress: an under appreciated 
mediator of neurodegeneration? Cell Signal 2007;19:219-28. 
191. Babior BM. Phagocytes and oxidative stress. Am J Med 2000;109:33-44. 
192. Wetle T. Living longer, aging better. Aging research comes of age. JAMA 
1997;278:1376-7. 
193. Green PS, Mendez AJ, Jacob JS, Crowley JR, Growdon W, Hyman BT, 
Heinecke JW. Neuronal expression of myeloperoxidase is increased in Alzheimer's 
disease. J Neurochem 2004;90:724-33. 
194. Leininger-Muller B, Hoy A, Herbeth B, Pfister M, Serot JM, Stavljenic-
Rukavina M, Massana L, Passmore P, Siest G, Visvikis S. Myeloperoxidase G-463A 
polymorphism and Alzheimer's disease in the ApoEurope study. Neurosci Lett 
2003;349:95-8. 
195. Reynolds WF, Hiltunen M, Pirskanen M, Mannermaa A, Helisalmi S, 
Lehtovirta M, Alafuzoff I, Soininen H. MPO and APOEepsilon4 polymorphisms 
interact to increase risk for AD in Finnish males. Neurology 2000;55:1284-90. 
196. Fraser PE, Nguyen JT, Chin DT, Kirschner DA. Effects of sulfate ions on 
Alzheimer beta/A4 peptide assemblies: implications for amyloid fibril-proteoglycan 
interactions. J Neurochem 1992;59:1531-40. 
197. Brooks G, Fahey T. Exercise Physiology. Human Bioenergetics and its 
Application. New York: Macmillan; 1984. 
198. Mecocci P, Cherubini A, Senin U, Polidori MC. Physical activity and oxidative 
stress during aging. International Journal of Sports Medicine 2000;21:154-7. 
199. BLOOMER RJ, SCHILLING BK, KARLAGE RE, LEDOUX MS, PFEIFFER RF, 
CALLEGARI J. Effect of Resistance Training on Blood Oxidative Stress in Parkinson 
Disease. Medicine & Science in Sports & Exercise 2008;40:1385-9 
10.249/MSS.0b013e31816f1550. 
200. Kim JD, Yu BP, McCarter RJ, Lee SY, Herlihy JT. Exercise and diet modulate 
cardiac lipid peroxidation and antioxidant defenses. Free Radic Biol Med 1996;20:83-
8. 
201. Poulsen HE, Loft S, Vistisen K. Extreme exercise and oxidative DNA 
modification. J Sports Sci 1996;14:343-6. 
	
79	
	
202. Sumida S, Doi T, Sakurai M, Yoshioka Y, Okamura K. Effect of a single bout 
of exercise and beta-carotene supplementation on the urinary excretion of 8-hydroxy-
deoxyguanosine in humans. Free Radic Res 1997;27:607-18. 
203. Kanter M. Free radicals, exercise and antioxidant supplementation. Proc Nutr 
Soc 1998;57:9-13. 
204. Tipton KD, Wolfe RR. Exercise-induced changes in protein metabolism. Acta 
Physiol Scand 1998;162:377-87. 
205. Angevaren M, Aufdemkampe G, Verhaar HJ, Aleman A, Vanhees L. Physical 
activity and enhanced fitness to improve cognitive function in older people without 
known cognitive impairment. Cochrane Database Syst Rev 2008:CD005381. 
206. Vaccarino V, Brennan ML, Miller AH, Bremner JD, Ritchie JC, Lindau F, 
Veledar E, Su S, Murrah NV, Jones L, Jawed F, Dai J, Goldberg J, Hazen SL. 
Association of major depressive disorder with serum myeloperoxidase and other 
markers of inflammation: a twin study. Biol Psychiatry 2008;64:476-83. 
207. Winker R, Lukas I, Perkmann T, Haslacher H, Ponocny E, Lehrner J, 
Tscholakoff D, Dal-Bianco P. Cognitive function in elderly marathon runners: cross-
sectional data from the marathon trial (APSOEM). Wien Klin Wochenschr 
2010;122:704-16. 
208. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke 
JP. The Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) statement: guidelines for reporting observational studies. . PLoS Med 
2007:e296. 
209. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting 
guidelines for health research. . Eur J Clin Invest 2010:35-53. 
210. Lehrner J, Gleiß A, Maly J, Auff E, Dal-Bianco P. Der Verbale Selektive 
Reminding Test (VSRT). Ein Verfahren zur Überprüfung verbaler 
Gedächtnisfunktionen. Neuropsychiatrie 2006;20:204-14. 
211. Lehrner J, Gufler R, Guttmann G, Maly J, Gleiss A, Auff E, Dal-Bianco P. 
Annual conversion to alzheimer disease among patients with memory complaints 
attending an outpatient memory clinic: the influence of amnestic mild cognitive 
impairment and the predictive value of neuropsychological testing. Wien Klin 
Wochenschr 2005;117:629-35. 
	
80	
	
212. Lehrner J, Maly J, Gleiß A, Auff E, Dal-Bianco PT. The Vienna 
Neuropsychological Test Battery (VNTB) for detecting dementia - standardization, 
norms, and validation. Psychologie in Österreich 2007;4 & 5:358-65. 
213. Lezak M. Neuropsychological assessment. New York: Oxford University 
Press; 1995. 
214. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, 
Mellits ED, Clark C. The Consortium to Establish a Registry for Alzheimer's Disease 
(CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's 
disease. Neurology 1989;39:1159-65. 
215. Folstein M, Folstein S, McHugh P. MMST. Mini-Mental-Status-Test 
(Deutschsprachige Fassung: J. Kessler, HJ Markowitsch, P. Denzler). Weinheim: 
Beltz; 1990. 
216. Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse 
PA, Grafman JH. Clock drawing in Alzheimer's disease. A novel measure of 
dementia severity. J Am Geriatr Soc 1989;37:725-9. 
217. Lehrl S, Fischer B, eds. cl-Kurztest für cerebrale Insuffizienz zur 
Frühdiagnostik von Demenzen. Ebersberg: Vless; 1997. 
218. Gatterer G. Alters-Konzentrations-Test (AKT). Göttingen: Hogrefe; 1990. 
219. Tewes U. Hamburg-Wechsler-Intelligenztest für Erwachsene. Revision 1991 
(HAWIE-R). Bern: Verlag Hans Huber; 1994. 
220. Reitan R. Trail Making Test (TMT). Tucson: Reitan Neuropsychology 
Laboratory; 1979. 
221. Oswald W, Fleischmann U. Das Nürnberger-Alters-Inventar. Göttingen: 
Hogrefe; 1997. 
222. Steiner M. Das alternde Gedächtnis: Grenzen und Perspektiven. Die MAC-
Gedächtnisbatterie. Diploma Thesis "Grund- und Integralwissenschaftliche Fakultät". 
Wien: Universität Wien; 1998. 
223. Regard M, Strauss E, Knapp P. Children's production on verbal and non-
verbal fluency tasks. Percept Mot Skills 1982;55:839-44. 
224. Schmidt K, Metzler P. Wortschatztest (WST). Bern: Verlag Hans Huber; 1992. 
225. WHO (Fünf) - FRAGEBOGEN ZUM WOHLBEFINDEN. 1998. (Accessed 
25.04.2011, at http://www.cure4you.dk/354/WHO-5_German.pdf.) 
	
81	
	
226. Bullinger M, Kirchberger I. SF-36. Fragebogen zum Gesundheitszustand. 
Handanweisung. Göttingen: Hogrefe; 1998. 
227. Hindmarch I, Lehfeld H, Jongh P, Erzigkeit H. B-ADL Skala zur Einschätzung 
der Alltagskompetenz. Göttingen: Hogrefe; 1999. 
228. Bach M, Nikolaus T, Oster P, Schlierf G. [Diagnosis of depression in the 
elderly. The "Geriatric Depression Scale"]. Z Gerontol Geriatr 1995;28:42-6. 
229. Hautzinger M, Bailer M, Worall H, Keller F. Beck-Depressions-Inventar (BDI). 
Bern: Verlag Hans Huber; 1994. 
230. Mahon NE, Yarcheski A, Yarcheski TJ. Psychometric evaluation of the 
personal lifestyle questionnaire for adolescents. Res Nurs Health 2002;25:68-75. 
231. Mahon NE, Yarcheski TJ, Yarcheski A. The revised Personal Lifestyle 
Questionnaire for early adolescents. West J Nurs Res 2003;25:533-47. 
232. Elliott P, Peakman TC. The UK Biobank sample handling and storage protocol 
for the collection, processing and archiving of human blood and urine. Int J Epidemiol 
2008;37:234-44. 
233. Lee DH, Kim JW, Jeon SY, Park BK, Han BG. Proteomic analysis of the effect 
of storage temperature on human serum. Ann Clin Lab Sci 2010;40:61-70. 
234. MUW Biobank Access Request. 2009. (Accessed 07.08.2010, at 
http://www.meduniwien.ac.at/akh-biobank/ac2.0.pdf.) 
235. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). 
Quantitative assay of immunoglobulin G. Immunochemistry 1971;8:871-4. 
236. R&D Systems I. Package Insert: Quantikine(R) Human MPO Immunoassay. 
In. http://www.rndsystems.com/pdf/DMYE00.pdf; 2010. 
237. Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H. Specific enzymatic 
amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harb Symp 
Quant Biol 1986;51 Pt 1:263-73. 
238. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N. 
Enzymatic amplification of beta-globin genomic sequences and restriction site 
analysis for diagnosis of sickle cell anemia. Science 1985;230:1350-4. 
239. London SJ, Lehman TA, Taylor JA. Myeloperoxidase Genetic Polymorphism 
and Lung Cancer Risk. Cancer Research 1997;57:5001-3. 
240. Polisson C, Morgan RD. AciI, a unique restriction endonuclease from 
Arthrobacter citreus which recognizes 5' CCGC 3'. Nucleic Acids Res 1990;18:5911. 
	
82	
	
241. Krugh TR, Wittlin FN, Cramer SP. Ethidium bromide–dinucleotide complexes. 
Evidence for intercalation and sequence preferences in binding to double-stranded 
nucleic acids. Biopolymers 1975;14:197-210. 
242. Le Pecq JB. Use of ethidium bromide for separation and determination of 
nucleic acids of various conformational forms and measurement of their associated 
enzymes. Methods Biochem Anal 1971;20:41-86. 
243. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific 
polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of 
Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A 1991;88:7276-80. 
244. Hui L, DelMonte T, Ranade K. Genotyping using the TaqMan assay. Curr 
Protoc Hum Genet 2008;Chapter 2:Unit 2 10. 
245. Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease 
assay. Genet Anal 1999;14:143-9. 
246. Livak KJ. SNP genotyping by the 5'-nuclease reaction. Methods Mol Biol 
2003;212:129-47. 
247. McGuigan FE, Ralston SH. Single nucleotide polymorphism detection: allelic 
discrimination using TaqMan. Psychiatr Genet 2002;12:133-6. 
248. Ranade K, Chang MS, Ting CT, Pei D, Hsiao CF, Olivier M, Pesich R, Hebert 
J, Chen YD, Dzau VJ, Curb D, Olshen R, Risch N, Cox DR, Botstein D. High-
throughput genotyping with single nucleotide polymorphisms. Genome Res 
2001;11:1262-8. 
249. Shen GQ, Abdullah KG, Wang QK. The TaqMan method for SNP genotyping. 
Methods Mol Biol 2009;578:293-306. 
250. Kim S, Misra A. SNP genotyping: technologies and biomedical applications. 
Annu Rev Biomed Eng 2007;9:289-320. 
251. Wenten M, Gauderman WJ, Berhane K, Lin PC, Peters J, Gilliland FD. 
Functional variants in the catalase and myeloperoxidase genes, ambient air pollution, 
and respiratory-related school absences: an example of epistasis in gene-
environment interactions. Am J Epidemiol 2009;170:1494-501. 
252. Garatachea N, Garcia-Lopez D, Jose Cuevas M, Almar M, Molinero O, 
Marquez S, Gonzalez-Gallego J. Biological and psychological monitoring of training 
status during an entire season in top kayakers. J Sports Med Phys Fitness 
2011;51:339-46. 
	
83	
	
253. Camus G, Pincemail J, Ledent M, Juchmes-Ferir A, Lamy M, Deby-Dupont G, 
Deby C. Plasma levels of polymorphonuclear elastase and myeloperoxidase after 
uphill walking and downhill running at similar energy cost. Int J Sports Med 
1992;13:443-6. 
254. Melanson SE, Green SM, Wood MJ, Neilan TG, Lewandrowski EL. Elevation 
of myeloperoxidase in conjunction with cardiac-specific markers after marathon 
running. Am J Clin Pathol 2006;126:888-93. 
255. Morozov VI, Pryatkin SA, Kalinski MI, Rogozkin VA. Effect of exercise to 
exhaustion on myeloperoxidase and lysozyme release from blood neutrophils. Eur J 
Appl Physiol 2003;89:257-62. 
256. Rosa EF, Takahashi S, Aboulafia J, Nouailhetas VL, Oliveira MG. Oxidative 
stress induced by intense and exhaustive exercise impairs murine cognitive function. 
J Neurophysiol 2007;98:1820-6. 
257. Lezak M. Neuropsychological Assessment 3. New York: Oxford University 
Press; 1995. 
258. Johnson JK, Lui LY, Yaffe K. Executive function, more than global cognition, 
predicts functional decline and mortality in elderly women. J Gerontol A Biol Sci Med 
Sci 2007;62:1134-41. 
259. Cahn-Weiner DA, Malloy PF, Boyle PA, Marran M, Salloway S. Prediction of 
functional status from neuropsychological tests in community-dwelling elderly 
individuals. Clin Neuropsychol 2000;14:187-95. 
260. Grigsby J, Kaye K, Baxter J, Shetterly SM, Hamman RF. Executive cognitive 
abilities and functional status among community-dwelling older persons in the San 
Luis Valley Health and Aging Study. J Am Geriatr Soc 1998;46:590-6. 
261. Henry JD, Phillips LH. Covariates of production and perseveration on tests of 
phonemic, semantic and alternating fluency in normal aging. Neuropsychol Dev 
Cogn B Aging Neuropsychol Cogn 2006;13:529-51. 
262. Gałecki P, Florkowski A, Bobińska K, Śmigielski J, Bieńkiewicz M, Szemraj J. 
Functional polymorphism of the myeloperoxidase gene (G-463A) in depressive 
patients. Acta Neuropsychiatrica 2010;22:218-22. 
263. Shih J, Datwyler SA, Hsu SC, Matias MS, Pacenti DP, Lueders C, et al. Effect 
of collection tube type and preanalytical handling on myeloperoxidase 
concentrations. Clin Chem 2008:1076-9. 
	
84	
	
264. Chang P-Y, Wu T-L, Hung C-C, Tsao K-C, Sun C-F, Wu LL, Wu JT. 
Development of an ELISA for myeloperoxidase on microplate: Normal reference 
values and effect of temperature on specimen preparation. Clinica Chimica Acta 
2006;373:158-63. 
265. Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: A flexible statistical 
power analysis program for the social, behavioral, and biomedical sciences. Behavior 
Research Methods 2007:175-91. 
266. Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses using 
G*Power 3.1: Tests for correlation and regression analyses. Behavior Research 
Methods 2009:1149-60. 
 
I tried to find all holders of the figure/table copyrights to get their permission to use 
their images in this work. If there still should be an infringe of copyright I request to 
contact me. 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
85	
	
7. 	CURRICULUM	VITAE	
Name Helmuth HASLACHER 
Geburtsdatum 10. September 1985 
Geburtsort Spittal/Drau, Ktn 
Eltern Erna Haslacher, Textilarbeiterin 
 Helmut Haslacher, Mühlenarbeiter 
Familienstand verlobt 
Kinder 1 Tochter 
Wohnort Urban-Loritz-Platz 8/2/75, 1070 Wien 
Tel mobil 0676/6022983 
E-Mail helmuth.haslacher@meduniwien.ac.at 
 
Schulbildung 
 
1996-2004 BRG mit naturwiss. Schwerpunkt, Spittal/Drau, Ktn. Maturiert 
mit ausgezeichnetem Erfolg. 
1996-1992 VS Mühldorf/Mölltal 
1991-1992 Vorschule Reisseck/Mölltal 
 
Universitäre Ausbildung 
 
2008-laufend Studium der Humanmedizin an der Medizinischen Universität 
Wien. Ergebnis des Eignungstests: unter den besten 5 %. 
2006-laufend Studium der Politikwissenschaft an der Universität Wien. 
2005-laufend Studium der Molekularen Biologie an der Universität Wien.  
 Absolvieren des Auswahlverfahrens als 2. der Rangliste. 
 
 
 
 
 
	
86	
	
Wissenschaftliche Praktika (Wahlbeispiele) 
 
2008 Prof. Ines Swoboda, Christian-Doppler-Labor für 
Allergieforschung, Institut für Pathophysiologie, MedUni Wien 
(Construction of recombinant pET17b containing Ole e 9)  
2010 Prof. Raute Sunder-Plassmann, Klinisches Institut für 
Medizinische und Chemische Labordiagnostik, MedUni Wien 
(Expression of wild type and 121Q mutant (rs1044498) human 
plasma cell glycogprotein-1/PC-1 in HEK293 cell line) 
2011 Dr. Thomas Perkmann, Klinisches Institut für Labormedizin, 
MedUni Wien (Plasma Myeloperoxidase level and MPO 
genotype: useful markers for prediction of MACE in male and 
smoking patients suffering from PAD) 
 
Berufliche Laufbahn 
 
2007-laufend Stv. Leitung und QM-Koordinator der MedUni Wien Biobank  
2009 Dr. Müller Marktforschung 
2008-2009 Tutor an der Universität Wien, Inst. für Biochemie 
2006 Eventpromotion Mediaprint AG 
2006 Ferialpraktikum Österr. Post AG, Schalterdienst 
2004-2005 Rettungssanitäter (Zivildienst), RK St. Johann i. T. 
2003 Ferialpraktikum im Gastronomiebereich 
 
Sonstige Tätigkeiten 
 
2009-2011 Vorsitzender der ÖH-FV Molekulare Biologie an der Uni Wien 
2007-2011 Vorsitzender der ÖH-StV Molekulare Biologie an der UniWien 
 
Skills und Kenntnisse 
 
2010-laufend Ausbildung zum Trainer in polit. Rhetorik nach ASG 
2010-laufend Interner Auditor ISO 9000 in Ausbildung (GALP) 
	
87	
	
2010-laufend SPSS Statistikapplikation (fundierte Anwenderkenntnisse) 
2010 QM-Beauftragter (GALP) 
2009 Gefahrengutbeförderung (VAMED) 
2004 Rettungssanitäter (Österreichisches Rotes Kreuz) 
2004 European Computer Driving License  
2003 Rhetorik und Präsentation (u.a. Institut „The Training“) 
 
Fremdsprachen 
 
Deutsch (Muttersprache) 
Englisch (Wort und Schrift) 
Latein (Maturaniveau) 
 
Wissenschaftliche Mitgliedschaften 
 
Österreichische Gesellschaft für Molekulare Biowissenschaften und Biotechnologie  
Bund Sozialdemokratischer AkademikerInnen 
 
Kongress- und Tagungsbesuche 
 
2010 „Summer Institute: Genetics, Ethics and Clinical Translation”, Egmond aan 
Zee, NL 
2008 Member of „Arbeitsgruppe zur Errichtung einer nationalen Biobank des 
BMWF“ , Graz, A 
2008 “ESF BIOBANKS 2008”, St. Filou, ESP 
2008 “Danubian Biobank Consortium: Meeting on Work Package 5: Scientific 
Strategy. Modul 1: Transdifferentiation and Pathomechanisms of Organ 
Dysfunction in the Metabolic Syndrome Complex”, Bratislava, SK 
2008 “Danubian Biobank Consortium: Genetic background of Chronic Renal 
Insufficiency and Kidney transplantation”, Vienna, A  
2007 „Gemeinsamer Kongress der ÖGLMKC und der DGKL“ , Vienna, A 
2007 „2. genXpress RealTime PCR/Corbett User Meeting “, Wr. Neudorf, A 
 
	
88	
	
Poster und Vorträge  
 
1. Haslacher, H, Perkmann, T, Gruenewald, J, Exner, M, Endler, G, 
Scheichenberger, V, Wagner, O & Schillinger, M: Plasma myeloperoxidase 
and peripheral arterial disease. KILM Institutsseminar, 2011, Talk. 
2. Slavka, G, Perkmann, T, Haslacher, H, Wagner, O & Endler, G: Mean platelet 
volume is a predictive parameter for overall vascular mortality and ischemic 
heart disease. Clin Chem Lab Med, 47: Poster: 220, 2009. 
3. Perkmann T, Endler, G, Haslacher, H, Rumpold, H, Slavka, G, Wagner, O, Exner, 
M, Minar, E & Schillinger, M: Plasma Myeloperioxidase (MPO) as an 
independent risk marker for major cardiovascular events in patients with 
peripheral artery disease. Clin Chem Lab Med, 47: Poster: 135, 2009. 
4. Haslacher, H, Perkmann T, Endler, G, Rumpold, H, Slavka, G, Wagner, O, Exner, 
M, Minar, E & Schillinger, M: Plasma Myeloperioxidase (MPO) as an 
independent risk marker for major cardiovascular events in patients with 
peripheral artery disease. Abbott Myeloperoxidase Investigator Meeting. 
Frankfurt/Neu Isenburg, 2009, Präsentation in absenz. 
5. Aschauer, S, Mittermayer, F, Wagner, C, Schmidt, W, Brunner, M, Haslacher, H, 
Wolzt, M & Müller, M: Association of a genetic variation on chromosome 
9p21.3 with reduced arterial vasodilator function in healthy volunteers . Basic 
& Clinical Pharmacology & Toxicology, 105: Talk: 21, 2009. 
6. Haslacher, H, Perkmann, T, Ponweiser, E, Dellago, S & O, W: Preanalytic factors 
influencing the quality of mRNA preparations from human PBMCs. ESF 
BIOBANKS 2008. St. Filou (ESP), Poster, 2008. 
7. Haslacher, H: The AKH Biobank initiative. Danubian Biobank Consortium: Genetic 
background of Chronic Renal Insuffieciency and Kidney tranplantation. Wien, 
2009, Talk. 
8. Kampitsch, T, Haslacher, H, Hojak, A, Reichhold, I, Marsik, C, Endler, G & 
Wagner, O: Evaluation of a semi automated sample storage and archiving 
system based on the Olympus PLA 2500. Clin Chem Lab Med, 45: Poster: 
A103, 2007. 
9. Haslacher, H, Kampitsch, T, Hojak, A, Marsik, C, Endler, G & Wagner, O: The 
AKH biobank initiative – bridging the gap between freedom of academic 
	
89	
	
research and protection of privacy. Clin Chem Lab Med, 45: Poster: A103, 
2007. 
 
Publikationen 
 
1. Haslacher, H, Perkmann, T, Lukas, I, Barth, A, Ponocny, E, Michlmayer, M, 
Scheichenberger, V, Wager, O  & Winker, R: Serum myeloperoxidase level 
and cognitive function in elderly marathon runners. (In Submission), 2011. 
2. Haslacher, H, Perkmann, T, Gruenewald, J, Exner, M, Endler, G, 
Scheichenberger, V, Wagner, O & Schillinger, M: Plasma myeloperoxidase 
and peripheral arterial disease. Eur J Clin Invest (in press), 2011. 
3. Slavka, G, Perkmann, T, Haslacher, H, Wagner, O & Endler, G: Mean platelet 
volume is a predictive parameter for overall vascular mortality and ischemic 
heart disease. Arterioscler Thromb Vasc Biol., 31(5): 1215-8, 2011. 
4. Wahrmann, M, Dohler, B, Ruhenstroth, A, Haslacher, H, Perkmann, T, Exner, M, 
Rees, AJ & Bohmig, GA: Genotypic diversity of complement component c4 
does not predict kidney transplant outcome. J Am Soc Nephrol, 22: 367-76, 
2011. 
5. Winker, R, Lukas, I, Perkmann, T, Haslacher, H, Ponocny, E, Lehrner, J, 
Tscholakoff, D & Dal-Bianco, P: Cognitive function in elderly marathon 
runners: Cross-sectional data from the marathon trial (apsoem). Wien Klin 
Wochenschr, 2010. 
6. Kovar, FM, Marsik, CL, Joukhadar, C, Perkmann, T, Haslacher, H, Schickbauer, 
T, Kyrle, PA, Wagner, OF & Endler, G: Coagulation factor VIII levels are 
associated with long-term survival - interactions with gender in a large 
hospital-based cohort. Wien Klin Wochenschr, 122: 334-40, 2010. 
7. Aschauer, S, Mittermayer, F, Wagner, CC, Schmidt, WM, Brunner, M, Haslacher, 
H, Wolzt, M & Muller, M: Forearm vasodilator reactivity in homozygous 
carriers of the 9p21.3 rs1333049 G>C polymorphism. Eur J Clin Invest, 40: 
700-5, 2010. 
8. Kovar, FM, Thallinger, C, Marsik, CL, Perkmann, T, Puhalla, H, Haslacher, H, 
Wrba, F, Wagner, OF, Gruenberger, T & Endler, G: The EGF 61A/G 
	
90	
	
polymorphism - a predictive marker for recurrence of liver metastases from 
colorectal cancer. Wien Klin Wochenschr, 121: 638-43, 2009. 
9. Grimm, G, Haslacher, H, Kampitsch, T, Endler, G, Marsik, C, Schickbauer, T, 
Wagner, O & Jilma, B: Sex differences in the association between albumin 
and all-cause and vascular mortality. Eur J Clin Invest, 39: 860-5, 2009.  
 
